Prof. Dr. med. Andreas Neubauer, Philipps-Universität Marburg und Universitätsklinikum Gießen und Marburg, Zentrum Innere Medizin, Klinik für Hämatologie, Onkologie, Immunologie

„Ich habe mich oft gefragt, warum man zu dem wird, was man ist. Ich selbst habe  eher zufällig  Medizin studiert. In Berlin (West), an der Freien Universität Berlin und Universität Hamburg / Promotion. Ein Vorteil der Medizin, finde ich, besteht darin, dass die eigentliche Berufswahl um etwa sechs Jahre aufgeschoben wird.

Man beginnt erst einmal mit dem Medizinstudium, ohne sich sofort festlegen zu müssen, und kann sich später in ganz unterschiedliche Richtungen entwickeln. Man kann zum Beispiel Chirurg werden – also jemand, der mit den Händen arbeitet und körperliche Erkrankungen operativ behandelt. Am anderen Ende steht der theoretische Mediziner, der sich vor allem mit wissenschaftlichen Grundlagen beschäftigt. Oder man entscheidet sich für die Psychiatrie, wo es um die Ursachen und die Behandlung seelischer Erkrankungen geht.

Gerade diese Vielfalt empfinde ich als etwas Befreiendes. Medizin eröffnet viele Möglichkeiten und verschiebt die Notwendigkeit einer endgültigen Entscheidung um mehrere Jahre und saß dann schließlich in einer Vorlesung im Klinikum Steglitz …“

---

---

Prof. Dr. med. Andreas Neubauer
Philipps-Universität Marburg und Universitätsklinikum Gießen und Marburg Zentrum Innere Medizin, Klinik für Hämatologie, Onkologie, Immunologie
ehemal. Direktor der Klinik für Innere Medizin und Hämatologie, Onkologie, Immunologie

Akademische Ausbildung:

1976: Abitur Gymnasium Zum Grauen Kloster Berlin
10/1976 – 05/1983 Humanmedizin, Berlin und Hamburg, Doktorarbeit bei Prof. Winkler in Hamburg, 1984.
1984 Promotion Universität Hamburg
1992 Habilitation, Innere Medizin, Freie Universität Berlin

Wissenschaftlicher und klinischer Werdegang:
2010 Ruf W3-Professur Universität Freiburg (abgelehnt)
2004 Ruf C4-Professur Universität Würzburg (abgelehnt)
ab 1999 C4-Professur Philipps-Universität Marburg
10/1996 – 12/1998 C3-Professur Technische Universität Dresden
10/1990 – 9/1996 Assistenzarzt, seit 1993 Oberarzt, Hämatologie, Onkologie, Klinikum Charlottenburg, Freie Universität Berlin
10/1988 – 9/1990 Postdoc Stipendium, Deutsche Forschungsgemeinschaft, Lineberger Comprehensive Cancer Center, Universität North Carolina in Chapel Hill, NC, USA, Dr. Edison T Liu
3/1986 – 9/1988 Assistenzarzt, Hämatologie, Onkologie, Klinikum Charlottenburg, Freie Universität Berlin
9/1985 – 2/1986 Postdoc Stipendium, Deutsche Forschungsgemeinschaft, Max-Planck-Institut für Biochemie, Martinsried
7/1984 – 8/1985 Assistenzarzt, Hämatologie, Onkologie, Klinikum Charlottenburg, Freie Universität Berlin
7/1983 – 6/1984 Assistenzarzt Nephrologie, Klinikum Charlottenburg, Freie Universität Berlin

Wissenschaftliche Aktivitäten / Auszeichnungen:

2022 Stellvertr. Vorstand José Carreras Leukämiestiftung 2021-2024 Vorstand Deutsche Gesellschaft für Innere Medizin 2023-2024 Vorsitzender der Deutschen Gesellschaft für Innere Medizin 2020 DFG Ausschuss Klinische Studien 2014 -2019 Hinterzartener Kreis der DFG, Leitungsgremium 2014 Mitglied der Leopoldina 2009 -2019 Ausschuss Klinische Studien der Krebshilfe (Ltg. ab 2014) 2008 -2013 Sprecher des Transregio SFB TRR17
„Ras-dependent pathways in human cancer“
2008 -2015 Sprecher der Klinischen Forschergruppe DFG KFO210
„Genetics of drug resistance in cancer“
2007 -2013 Leiter des wiss. Beirats der José Carreras Leukämiestiftung 2005 – 2008 Faculty Hematology, European Society Medical Oncology 2002 -2013 Sprecher des Comprehensive Cancer Center Marburg 2000 Wiss. Beirat der José Carreras Leukämiestiftung 1997 – 2003 Vorstand Deutsche Gesellschaft Hämatologie und Onkologie

Wissenschaftliche Schwerpunkte:
Genetik myeloischer Leukämien Molekularbiologie der Resistenz Rolle der Helicobacter pylori Infektion bei Magenlymphomen

Ehrungen/Preise:

2008: Hessischer Landeslehrpreis (dritter Platz) für curriculum oncologicum 2006: Wilhelm-Warner Preis für Krebsforschung 1988: Stipendium der DFG (Postdoc; Lineberger Cancer Center, Chapel Hill) 1985: Stipendium der DFG (Postdoc, MPI Biochemie Martinsried)

Drittmittelförderung der letzten 10 Jahre:

DFG mit SFB-TRR17, KFO 210, SPP1463 BMBF Carreras Stiftung (inkl. Bau des Carreras Leukämie Centrum) Dt. Krebshilfe Wilhelm-Sander-Stiftung andere lokale Stiftungen
Insgesamt ca. 5 Mio Euro

________________________

Eigene Veröffentlichungen
1.
Neubauer A, Thalmann U, Musch R, Grosser H, Loddenkemper R,Huhn D: Prospektiver Vergleich der diagnostischen Wertigkeit vonZytologie und Immunzytologie bei thoraskopisch-bioptisch unter suchten Pleuraergüssen. Klin Wschr 65: 400-406, 19871

2.
Neubauer A, Sauer H, Valet G: Cytostatic drug testing in humanleukemias by means of multiparametric flow cytometry.Blut 55: 433-445, 1987

3.
Neubauer A, Huhn D: Monoclonal antibody Ki67 as aproliferation marker. (Letter) Br J Haematol 67: 495, 1987

4.
Neubauer A: Reizhusten durch ACE-Hemmer: Dosierungsschema bedenken. (Leserbrief) Münch Med Wochenschr 129: 18, 1987

5.
Pralle H, Zwingers T, Boedewadt S, Bross K, Dörken B, Gamm H,Ho AD, Parwaresch RM, Schmitz N, Papendick U, Asshoff D, Bremer K,Euler H, Fischer T, Ganser A, Goldmann A, Hartlapp J, Hazungs J,Heinen U, Heyll A, Kraft J, Lohmeyer J, Meier P, Neubauer A,Nowicki L, Pflüger K, Sass R, Schmidt W, Schuster D, Straif K,Westerhausen M: Primäre Behandlung der Haarzelleukämie mitniedrigdosiertem humanem rekombinantem IFNalpha2c im Vergleichzur Therapie nach Splenektomie. Onkologie 10: 5-10, 1987.

6.
Pralle H, Zwingers T, Boedewadt S, Bross K, Doerken B, Gamm H,Ho AD, Parwaresch RM, Schmitz N, Papendick U, Asshoff D, Bremer K,Euler H, Fischer T, Ganser A, Goldmann A, Hartlapp J, Hayungs J,Heinen U, Heyll A, Kraft J, Lohmeyer J, Meier P, Neubauer A,Nowicki L, Pflüger K, Sass R, Schmidt W, Schuster D, Straif K,Westerhausen M: A prospective multicenter trial with humanrecombinant alpha2c interferon in hairy cell leukemia before andafter splenectomy. Leukemia 1:337-40, 1987

7.
Neubauer A, Musch R, Thalmann U, Laser J, Grosser H, Loddenkem­per R, Huhn D: Evidence for cross reactivity of „carcinoma­specific“ monoclonal antibody KC4 with activated mesothelial cellsand phytohemagglutinin stimulated lymphocytes.Oncology 45:380-3, 1988

8.
Schmidt CA, Fiek T, Neubauer A, Huhn D: HIV Infektion durchNadelstichverletzung (Leserzuschrift). Deut Med Wschr 113: 76,1988

9.
Pralle H, Bartel A, Boedewadt S, Bross K, Bruhn HD, DörkenB,.Drees N, Essers U, Fuhr H, Gamm H, Ho AD, Parwaresch RM, Papendick U, Asshoff D, Bremer K, Euler H, Fischer T, Ganser A,Vonnegut A, Hayungs J, Heinen U, Heyll A, Kraft J, Neubauer A,Nowicki L, Pfannschmidt G, Pflüger K, Sass R, Schmidt W, SchusterD, Schober I, Schrappe-Bächer M, Schwöbel HD, Straif K, Vaupel H, Zwingers T: Interferon alpha für die Therapie der HCL: Ergebnissevon drei prospektiven multizentrischen Studien in der BRD. Onkologie 11: 44-47, 1988.

10.
Siegert W, Huhn D, Neubauer A, Brittinger G, Engelhard M etal: Multizentrische prospektive risikoadaptierte Studie zurTherapie von Non-Hodgkin Lymphomen hoher Malignität. Onkologie 11: 30-34, 1988.

11.
Neubauer A, v.Lessen A, Huhn D: Methodenabhängigkeit der T-Zellsubpopulationsbestimmung. Dtsch Med Wschr, 114:414-416, 1989.

12.
Neubauer A, Serke S, Siegert W, Kroll W, Musch R, Huhn D: Aflow cytometric assay for the determination of cell proliferationwith a monoclonal antibody directed against DNA-methyltransferase. Br J Haematol 72:492-496, 1989.

13.
Serke S, Neubauer A, Huhn D: Expression of transferrinreceptor parallels state of proliferation in HL60 cells. (letter)Br J Haematol 72:297-299, 1989.

14.
Serke S, Neubauer A, Huhn D: Lymphocytosis of large granularlymphocytes: proof of monoclonality of the LGL population andbenign clinical course. Klin Wschr 67:588-591, 1989.

15.
Serke S, Stein H, Anagnostopoulos I, Schmidt C, Neubauer A,Siegert W, Huhn D: Acute leukemia with B and T-lymphoid and myeloid characteristics in a patient with a myelodysplastic syn­drome: a case report. Br J Haematol 72:110-111, 1989.

16.
Serke S, Neubauer A, van Lessen A: Binding of mitogenic plantlectins to human lymphocyte subpopulations: a flow cytometricanalysis. J Immunol Methods 121:231-235, 1989.

17.
Neubauer A, Herbst H, Rochlitz C, Siegert W, Schmidt C, Huhn

1 (Impactfaktoren (IF) ab 1990 gelistet, nach:http://www.ldeo.columbia.edu/~dery/if99.htm)
D: Immunocytochemical detection of p21 ras expression in freshhuman leukemic cells and cell lines lines. Blut 59:460-463, 1989.
18.
Cogswell PC, Morgan R, Dunn M, Neubauer A, Nelson P, Poland-Johnston NK, Sandberg AA, Liu E: Mutations of the ras protoonco­genes in chronic myelogeneous leukemia: a high incidence of rasmutations in bcr/abl negative CML. Blood 74:2629-2633, 1989.

19.
Thompson-Moya L, Martin T, Heuft HG, Neubauer A, Herrmann R:Case report: Allergic reaction with immune hemolytic anemiaresulting from chlorambucil. Amer J Hematol 32:230-231, 1989.

20.
Neubauer A, Valet G, Huhn D: Flow cytometric determination ofintracellular pH, esterase-concentration and cell-volume in human leukemic cell lines following in-vitro cytostatic drug incubation. Anal Cell Pathol 2:49-58, 1989.

21.
Neubauer A, Neubauer B, Liu E: Polymerase chain reaction basedassay to detect allelic loss in human DNA: Loss of beta-interferon gene in chronic myelogeneous leukemia. Nucl Acids Res 18: 993-998, 1990. IF: 5.7

22.
Grosser H, Neubauer A, Musch R, Thalmann U, Huhn D, Lodden­kemper R: CEA as a tumor marker on the cell surface and in theexsudate: Comparison in thoracoscopy examined pleural effusions.Pneumologie 44, Suppl 1: 529-530, 1990.IF: ­

23.
Ball ED, Mills LE, Neubauer A, Liu E: Detection of minimalacute myeloid leukemia cells in bone marrow by probing for mutatedras oncogenes using the polymerase chain reaction. Prog Clin BiolRes 333: 499-506, 1990.IF: 0.7

24.
Neubauer A, Shannon K, Liu E: Mutations of the ras proto­oncogenes in childhood monosomy 7. Blood 77 (3): 594-598, 1991.IF: 8.7

25.
Chen L, Neubauer A, Kurisu W, Waldman F, Ljung B, Goodson W,Goldman E, Moore D, Balazs M, Liu E, Mayall B, Smith H: A geneother than p53 on the short arm of chromosome 17 is associatedwith high proliferative capacity and DNA aneuploidy in primaryhuman breast cancer. Proc Natl Acad Sci USA, 88:3847-51.IF: 10.2

26.
O’Bryan J, Frye RA, Cogswell P, Neubauer A, Kitch B, Prokop C,Espinoza R, Le Beau MM, Earp HS, Liu E: axl, a transforming geneisolated from primary human myeloid leukemia cells, encodes anovel receptor tyrosine kinase. Mol Cell Biol 11:5016-5031, 1991.IF: 9.8

27.
Effert P, Frye RA, Neubauer A, Liu E, Walther P: Humanpapillomavirus subtypes 16 and 18 are not involved in humanprostate carcinogenesis: Analysis of archival human prostatecancer specimens by differential polymerase chain reaction. JUrol, 147:192-196, 1992.IF: 2.4

28.
Effert P, Neubauer A, Walther P, Liu E: Alterations of the p53gene are associated with the progression of a human prostatecarcinoma. J Urol 147: 789-793, 1992. IF: 2.4

29.
Neubauer A, Neubauer B, He M, Effert P, Iglehart D, Frye RA, Liu E: Technical report: Analysis of gene amplification inarchival tissue by differential polymerase chain reaction.Oncogene 7(5): 1019-1025, 1992.IF: 6.5

30.
Schmidt CA, Oettle H, Neubauer A, Seeger KH, Thiel E, Huhn D,Siegert W, Ludwig WD: Rearrangements of T-cell receptor delta, gamma and beta genes in acute myeloid leukemia coexpressing T­lymphoid features. Leukemia 6:1263-1267, 1992.IF: 3.5

31.
Taylor J, Sandler D, Bloomfield C, Shore D, Ball E, Neubauer A, McIntyre R, Liu E: ras oncogene activation and occupationalexposure in acute myeloid leukemia. J Natl Cancer Inst, 84:1626­1632, 1992.IF: 12.9

32.
Rochlitz CR, de Kant E, Neubauer A, Heide I, Böhmer R, Huhn D,Herrmann R: mdr1 expression in chronic lymphocytic leukemia. AnnHematol, 65: 241-246, 1992.IF: 1.1

33.
Neubauer A, He M, Schmidt CA, Huhn D, Liu E: Geneticalterations in the p53 gene in the blast crisis of chronicmyelogeneous leukemia: Analysis by polymerase chain reaction basedtechniques. Leukemia 7: 593-600, 1993.IF: 3.5

34.
Neubauer A, O`Bryan JP, Fiebeler A, Schmidt CA, Huhn D, Liu E:axl, a novel receptor tyrosine kinase isolated from cells ofchronic myelogeneous leukemia. Sem Hematol 30 (3, Suppl 3): 34,1993. IF: 4.9

35.
Neubauer A, de Kant E, Rochlitz Ch, Laser J, Zanetta M, OertelJ, Herrmann R, Huhn D: Altered expression of the retinoblastomagene in chronic lymphocytic leukemia. Br J Haematol, 85: 498-503, 1993. IF: 3.2

36.
Rochlitz C, Heide I, de Kant E, Neubauer A, Schmidt CA,Neuhaus P, Huhn D, Herrmann R: Molecular alterations in a patientwith Turcot’s syndrome. Br J Cancer, 68:519-23, 1993.IF: 3.2

37.
Neubauer A, Brendel C, Vogel D, Schmidt CA, Heide I, Huhn D:Detection of p53 mutations using non-radioactive SSCP-analysis: p53 is not frequently mutated in myelodysplastic syndromes. AnnHematol, 67:223-226, 1993.IF: 1.1

38.
Seelig R, Schranz P, Bottner C, Neubauer A, Seelig HP, Renz M:The chronic myelocytic cell line K562 contains minor (m) as wellas major (M) BCR/ABL fusion mRNAs. Leukemia 7, 1886-1887, 1993.IF: 3.5

39.
Lefterova P, Negrin R, Neubauer A, Huhn D, Blume K, Schmidt-Wolf I: Efficient generation and characterization of tumor cellsubclones with different adhesion pathways involved in cell lysis.Hematologica, 78: 353-358, 1993IF: 2

40.
Schmidt CA, Przybylsky G, Vogel D, Ludwig WD, Oettle H,Neubauer A, Siegert W: ras point mutations occur in acute myeloidleukemias with illegitimate T-cell receptor delta gene rearrangement. Leukemia 8, 102-105, 1994.IF: 3.5

41.
Neubauer A, Greenberg P, Negrin R, Ginzton N, Liu E: Mutationsin the ras protooncogene in patients with myelodysplasticsyndromes. Leukemia, 8: 638-641, 1994.IF: 3.5

42.
Neubauer A, Dodge R, George St, Davey FR, Silver R, SchifferCh, Mayer RJ, Ball E, Wurster-Hill D, Bloomfield C, Liu E: Prognostic importance of mutations in the ras protooncogenes in de novo acute myeloid leukemia. Blood, 83: 1603-1611, 1994.IF: 8.7

43.
Schmidt CA, Neubauer A, Seeger KH, Rochlitz CR, Binder T,Oettle H, Henze G, Liu E, Huhn D, Siegert W: Detection of allelicloss within the ß1-interferon gene in childhood acute lymphoblastic leukemia using differential PCR. Ann Hematol, 68:171-174, 1994. IF 1.1

44.
Jörres A, Gahl G, Topley N, Neubauer A, Ludat K, Müller C,Passlick-Deetjen J: in vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose polymer based solutions. Nephrology Dialysis Transplantation, 9: 785-790, 1994. IF: 1.7

45.
Neubauer A, Fiebeler A, Graham DK, O’Bryan JP, Schmidt CA,Barckow P, Serke S, Siegert W, Snodgrass HR, Huhn D, Liu ET: The

expression of axl, a transforming receptor tyrosine kinase, innormal and malignant hematopoiesis. Blood 84: 1931-1941, 1994.IF: 8.7

46.
Topley N, Petersen MM, Mackenzie R, Neubauer A, Stylianou E,Kaever V, Davies M, Coles GA, Jörres A, Williams JD: Humanperitoneal mesothelial cell prostaglandin synthesis: induction ofcyclooxygenase mRNA ma peritoneal macrophage-derived cytokines. Kidney Int, 900-909, 1994.IF: 3.8

47.
Schmidt-Wolf IGH, Huhn D, Neubauer A, Wittig B: Clinicalprotocol: interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma.Human gene therapy 5:1161-1168, 1994. IF: 6.4

48.
Neubauer A, Liu E: Respiratory burst activity in MDS and MPSpatients. Br J Haematol 88 (3): 663-664, 1994.IF: 3.2

49.
Vogel D, Heide I, Stenzel E, Thiede C, Rochlitz C, Neubauer A: SSCP-Analyse von Mutationen im p53-Tumorsuppressor-Gen mittels Hydrolink-Gel-Elektrophorese. Serva News 4: 25-26, 1994. IF: ­

50.
Scheffold C, Brand K, Johnston V, Lefterova P, Degen B,Schöntube M, Huhn D, Neubauer A, Schmidt-Wolf IGH: Potential of autologous immunologic effector cells for bone marrow purging inpatients with chronic myeloid leukemia. Bone marrowtransplantation 15:33-39, 1995. IF: 2.2

51.
Ritter M, de Kant E, Huhn D, Neubauer A: Detection of calcitonin gene methylation in human leukemias using differentialpolymerase chain reaction. Leukemia 9: 915-922, 1995.IF: 3.5

52.
Bayerdörffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, EidtS, Stolte M, and the MALT lymphoma study group: Regression ofprimary gastric lymphoma of mucosa associated lymphoid tissueafter cure of Helicobacter pylori infection. Lancet 345:1591-1594, 1995. IF: 10.1

53.
Thiede C, Bayerdörffer E, Blasczyk R, Wittig B, Neubauer A: Simple and sensitive detection of mutations in the rasprotooncogenes using PNA-mediated PCR clamping. Nucl Acids Res, 24: 983-4, 1996.IF: 5.7

54.
Blasczyk R, Ritter M, Thiede C, Wehling J, Hintz G, Neubauer A, Riess H: Simple and rapid detection of factor V Leiden byallele-specific PCR amplification. Thrombosis and Haemostasis, 75: 757-759, 1996.IF: 4.9

55.
Unterhalt M, Herrmann R, Tiemann M, Parwaresch R, Stein H,Trümper L, Nahler M, Reuss-Bost M, Tirier C, Neubauer A, Freund M,Kreuser E, Dietzfelbinger H, Bodenstein H, Engert A, Stauder R,Eimermacher H, Landys K, Hiddemann W: Prednimustine, mitoxantrone(PmM) vs. cyclophosphamide, vincristine, prednisone (COP) for thetreatment of advanced low-grade non-Hodgkin’s lymphoma. Leukemia 10: 836-843, 1996.IF: 3.5

56.
Aulitzky WE, Neubauer A, Kolbe K, Schneller F, Busemann C,Schleiermacher E, Peschel C, Siegert W, Huber C, Huhn D:Preliminary results of stem cell mobilization in chronic myeloidleukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3. Bone marrow transplantation 17, Suppl 3, S67­S69, 1996.IF: 2.2

57.
Nagel S, Schmidt M, Thiede C, Huhn D, Neubauer A: Quantification of bcr-abl transcript numbers in chronic myelogenous leukemia using standardized, internally controlledcompetitive differential PCR. Nucleic Acids Res, 24: 4102-4103, 1996. IF: 5.7

58.
Riewald M, Hintz G, Ritter M, Schmidt M, Neubauer A, Riess H:High sensitivity and specificity of a coagulation assay for thedetection of heterozygous and homozygous factor V Leiden basedresistance to activated protein C (Letter). Blood, 88: 4398-4399, 1996. IF: 8.7

59.
Seliger B, Papadileris S, Vogel D, Hess G, Brendel C, StörkelS, Oertel J, Kolbe K, Huber C, Huhn D, Neubauer A: Analysis of thep53 and MDM-2 gene in acute myeloid leukemia. Eur J Haematol 57: 230-240, 1996.IF: 1.4

60.
Neubauer A, Burchert A, Maiwald C, Gruss HJ, Serke S, Huhn D,Wittig B, Liu E: Recent progress on the role of axl, a receptortyrosine kinase, in malignant transformation of myeloid leukemias.Leuk Lymphoma, 25: 91-96, 1997.IF: 1.1

61.
Mackenzie RK, Topley N, Neubauer A, Coles GA, Williams JD:Staphylococcal exoproducts down-regulate cyclooxygenase 1 and 2 in peritoneal macrophages. J Lab Clin Med 129: 23-34, 1997.IF: 1.9

62.
Rudolph B, Bayerdörffer E, Ritter M, Müller S, Thiede C,Neubauer B, Lehn N, Seifert E, Otto P, Hatz R, Stolte M, Neubauer

A: Is the polymerase chain reaction or cure of Helicobacter pyloriinfection of help in the differential diagnosis of early gastricMALT lymphoma? J Clin Oncol, 15: 1104-1109, 1997.IF: 7.9
63.
Heide I, Thiede C, Sonntag T, Kant E, Neubauer A, Jonas S,Peter F, Neuhaus P, Herrmann R, Rochlitz C: The role of p53 in themetastatic progression of colorectal cancer. Eur J Cancer, 33:1314-1322, 1997. IF: 2.5

64.
Bayerdörffer E, Miehlke S, Neubauer A, Stolte M: Gastric MALT­lymphoma and Helicobacter pylori infection. Aliment PharmacolTher, 11 Suppl 1: 89-94, 1997.IF: 3.0

65.
Neubauer A, Thiede C, Morgner A, Alpen B, Ritter M, Neubauer B, Wündisch T, Ehninger G, Stolte M,Bayerdörffer E: Cure ofHelicobacter pylori infection and duration of remission of low­grade gastric MALT lymphoma. J Natl Cancer Inst 89: 1350 -1355,1997. IF: 12.9

66.
Sackmann M, Morgner A, Rudolph B, Neubauer A, Thiede C, SchulzHD, Kraemer W, Boersch G, Rohde P, Seifert E, Stolte M,Bayerdörffer E: Regression of gastric MALT lymphoma aftereradication of Helicobacter pylori is predicted by endosonographicstaging. Gastroenterology 113: 1087 -1090, 1997.IF: 12.1

67.
Finke S, Trojaneck B, Möller P, Schadendorf D, Neubauer A,Huhn D, Schmidt-Wolf IG: Increase of cytotoxic sensitivity of primary human melanoma cells transfected with the interleukin-7 gene to autologous and allogeneic immunologic effector cells.Cancer Gene Ther 4: 260-268, 1997. IF: 4.1

68.
Ritter M, Thiede C, Schäkel U, Schmidt M, Alpen B, PaschebergU, Mohr B, Ehninger G, Neubauer A: Underestimation of inversion

(16) in acute myeloid leukemia using standard cytogenetics ascompared with polymerase chain reaction: Results of a prospectiveinvestigation. Br J Haematol 98: 969 -972, 1997.IF: 3.5
69.
Ruhnke M, Grosch-Wörner I, Steinmüller A, Neubauer A: Molekulare Epidemiologie von Candida-Infektionen bei HIV-infizierten Müttern und ihren Kindern. Wiener Med. Wschr. 147: 446 -449; 1997.IF: ­

70.
Thiede C, Morgner A, Alpen B, Wündisch T, Herrmann J, RitterM, Ehninger G, Stolte M, Bayerdörffer E, Neubauer A: What role does Helicobacter pylori eradication play in gastric MALT andgastric MALT lymphoma? Gastroenterology 113(6 Suppl):S61-S64, 1997 IF: 12.1

71.
Schmidt M, Nagel S, Proba J, Thiede C, Ritter M, Waring JF,Rosenbauer F, Huhn D, Wittig B, Horak I, Neubauer A: Lack of interferon consensus sequence binding protein (ICSBP) transcriptsin human myeloid leukemias. Blood, 91:22-29, 1998IF: 8.7

72.
Riewald M, Chuang T, Neubauer A, Riess H, Schleef RR:Expression of bomapin, a novel human serpin, in normal / malignanthematopoiesis and the monocytic cell lines THP-1 and AML-193. Blood 91: 1256-1262, 1998. IF: 8.7

73.
Bornhäuser M, Mohr B, Ehrenlechner U, Neubauer A, Ehninger G:Fluorescence in situ hybridization for the BCR/ABL rearrangementis dependent on the percentage of non-lymphocytic cells in peripheral blood stem cell harvests. J Hematotherapy, 7: 425-430, 1998. IF: 3.1

74.
Hiddemann W, Unterhalt M, Herrmann R, Wöltjen HH, Kreuser ED,Trümper L, Reuss-Borst M, Terhardt-Kasten E, Busch M, Neubauer A,Kaiser U, Hanrath RD, Middeke H, Helm G, Freund M, Stein H,Tiemann M, Parwaresch R: Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy comparedwith follicle-center lymphomas: Results of a prospective comparative analysis of the German low-grade lymphoma study group. J Clin Oncol 16: 1922-1930, 1998.IF: 7.9

75.
Fischer T, Neubauer A, Mohm J, Huhn D, Busemann C, Link H,Arseniev L, Büssing B, Novotny J, Ganser A, Duyster J, Bunkes D,Kreiter S, Aulitzky W, Hehlmann R, Huber C: Chemotherapy inducedmobilization of karyotypically normal PBSC for autografting inCML. Bone Marrow Transplantion 21: 1029-1036, 1998.IF: 2.2

76.
Neubauer A, Thiede C, Neubauer B, Ehninger G, Bayerdörffer E,Stolte M: Response to Dr. Seymour; Cure of Helicobacter pyloriinfection and duration of remission in low-grade gastric mucosa­

associated lymphoid tissue lymphoma (Correspondence). J NatlCancer Inst 90: 164, 1998.IF: 12.3

77.
Thiede C, Alpen B, Morgner A, Schmidt M, Ritter M, Ehninger G, Stolte M, Bayerdörffer E, Neubauer A: Ongoing somatic mutationsand clonal expansions after cure of Helicobacter pylori infectionin gastric mucosa associated lymphoid tissue (MALT) B-cell lymphoma. J Clin Oncol 16: 3822-3831, 1998.IF: 7.9

78.
de Mas CR, Sefert E, Stolte M, Neubauer A, Thiede C: Anunusual course of a low-grade non-Hodgkin´s lymphoma of the stomach. Z Gastroenterol 36: 567-569, 1998.IF: 0.8

79.
Baurmann H, Nagel S, Binder T, Neubauer A, Siegert W, Huhn D:Kinetcs of the graft-versus leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia afterallogeneic bone marrow transplantation. Blood 92: 3582-3590, 1998.IF: 8.7

80.
Müller M, Scheffold C, Lefterova P, Huhn D, Neubauer A,Schmidt-Wolf IGH: Potential of autologous immunologic effector cells for prediction of progression of disease in patients withchronic myelogeneous leukemia. Leuk Lymphoma 31: 335-341, 1998.IF: 1.1

81.
Heide I, Sokoll AC, Henz BM, Nagel S, Kreissig K, Grutzkau A,Grabbe J, Wittig B, Neubauer A. Regulation and possible functionof axl expression in immature human mast cells. Ann Hematol 77:199-205, 1998.IF: 1.1

82.
Baurmann H, Thiede C, Nagel S, Neubauer A, Siegert W, Huhn D:Chimerism following donor lymphocyte infusion for chronic myeloidleukemia (Correspondence). Blood 93: 2748-49, 1999.IF: 8.7

83.
Thiede C, Florek M, Bornhäuser M, Ritter M, Mohr B, Brendel C,Ehninger G, Neubauer A: Rapid quantification of mixed chimerismusing multiplex amplification of short tandem repeat markers andfluorescence detection. Bone Marrow Transplantation 23: 1055-60, 1999. IF: 2.2

84.
Rochlitz C, Lohri A, Bacchi M, Schmidt M, Nagel S, Fopp M, FeyMF, Herrmann R, Neubauer A: Axl expression is associated withadverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): Results from a multicenter trial of

the Swiss Group for Clinical Cancer Research (SAKK). Leukemia, 13:1352 -1358, 1999.IF: 3.5

85.
Schmidt Wolf, IGH, Finke S, Trojanek B, Denkena A, LefterovaP, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T,Neubauer A, Wittig B, Huhn D: Phase I clinical study applyingautologous immunologic effector cells transfected with theinterleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. British Journal of Cancer 81:1009-16, 1999.IF: 3.2

86.
Brendel C, Mohr B, Schimmelpfennig C, Müller J, Bornhäuser M,Schmidt M, Ritter M, Ehninger G, Neubauer A: Detection of cytogenetic aberrations in CD90 (Thy-1) positive and negative stem cell (CD34) subfractions of patients with acute and chronicmyeloid leukemias. Leukemia, 13:1770-1775, 1999.IF: 3.5

87.
Illmer T, Schaich M, Oelschlägel U, Nowak R, Renner U, ZiegsB, Subat S, Neubauer A, Ehninger G: A new PCR Mimic strategy toquantify low mdr1 mRNA levels in drug resistant cell lines and AMLblast samples. Leuk Res 23: 653-663, 1999.IF: 1.1

88.
Bornhäuser M, Thiede C, Brendel C, Geissler G, Oelschlägel U,Neubauer A, Ehninger G: Stable engraftment after megadose bloodstem cell transplantation across the HLA barrier. Transplantation63: 87-88, 1999.IF: 3.4

89.
Burchert A, Notter M, Menssen HD, Schwartz S, Knauf W,Neubauer A, Thiel E: CD82 (Kai 1) , a member of the tetraspaninfamily, is expressed on early hematopoietic progenitor cells andup-regulated in distinct human leukemias. Br J Haematol 107: 494­504, 1999.IF: 3.2

90.
Ruhnke M, Grosch-Wörner, I, Lischewski A, Neubauer A,Steinmüller A, Trautmann M, Morschhäuser J: Genotypic relatednessof yeast isolates from women infected with human immunodeficiencyvirus and their children. Mycoses 42: 385-394, 1999.IF: 0.7

91.
Lindauer M, Domkin D, Döhner H, Kolb H, Neubauer A, Huhn D,Kreiter H, Koch B, Huber C, Aulitzky W, Fischer T: Efficacy andtoxicity of IFN-alpha2b combined with cytarabine in chronic myelogeneous leukemia. Br J Haematol 106: 1013-19, 1999.IF: 3.2

92.
Ochsenkühn T, Bayerdörffer E, Meining A, Schinkel M, Thiede C,Nussler V, Sackmann M, Hatz R, Neubauer A, Paumgartner G: Colonicmucosal proliferation is related to serum deoxycholic acid levels.Cancer 85: 1664-69, 1999IF: 3.6

93.
Behn M, Thiede C, Neubauer A, Pankow W, Schuermann M:Facilitated detection of oncogene mutations from exfoliated tissuematerial by a PNA mediated enriched PCR protocol. J Pathol 190,190: 69-75, 2000.IF: 3.8

94.
Alpen B, Dierlamm J, Marynen P, Thiede C, Bayerdörffer E,Stolte M, Neubauer A: The translocation t (11; 18) is absent inearly gastric marginal zone B-cell lymphoma of MALT type responding to cure of Helicobactter pylori infection (letter).Blood 2000, 95: 4014-4015, 2000.IF: 8.7

95.
Morgner A, Lehn N, Andersen LP, Thiede C, Bennedsen M,Trebesius K, Neubauer B, Neubauer A, Stolte M, Bayerdörffer E:Helicobacter Heilmannii associated primary gastric low grade MALTlymphoma: Complete remission after curing the infection.Gastroenterology 118: 821-828, 2000.IF: 12.1

96.
Schmidt M, Hochhaus A, König-Merediz SA, Brendel C, Proba J, Hoppe G, Wittig B, Ehninger G, Hehlmann R, Neubauer A: Expressionof interferon regulatory factor 4 in chronic myeloid leukemia:Correlation with response to interferon-alpha therapy. J Clin Oncol. 18: 3331-3338, 2000. IF: 7.9

97.
Bornhäuser M, Thiede C, Schuler U, Platzbecker U, Freiberg-Richter J, Helwig A, Plettig R, Röllig C, Naumann R, KroschinskyF, Neubauer A, Ehninger G: Dose reduced conditioning forallogeneic blood stem cell transplantation: durable engraftmentwithout antithymocyte globulin. Bone Marrow Transplantation 26:119-125, 2000. IF: 2.2

98.
Schmidt M, Müller J, Proba J, Ehninger G, Neubauer A: Transfection of receptor tyrosine kinase axl into humanhaematopoietic cells does not cause spontaneous cellularaggregation (Correspondence). Br J Haematol 110: 1004 – 1005,2000. IF: 3.2

99.
König Merediz SA, Schmidt M, Hoppe GJ, Alfken J, Meraro D,Levi BZ, Neubauer A, Wittig B: Cloning of the interferon

regulatory factor 2 isoform with different regulatory activity.Nucl Acids Res 28: 4219-4224, 2000.IF: 5.7

100.
Hildebrandt B, Heide I, Thiede C, Nagel S, Dieing A, Jonas S,Neuhaus P, Rochlitz C, Riess H, Neubauer A: Lack of pointmutations in exons 11-23 of the retinoblastoma susceptibility gene RB-1 in liver metastases of colorectal carcinoma. Oncology 59: 344-346, 2000.IF: 2.6

101.
Scheffold C, Schöttker B, Lefterova P, Csipai M, GlasmacherA, Huhn D, Neubauer A, Schmidt Wolf IGH: Increased sensitivity ofmyeloid leukemia cell lines: Potential of lovastatin as bonemarrow purging agent. Acta Haematologica 104: 72-79, 2000.IF: 1.1

102.
Dennhardt N, Gorg C, Neubauer A.: Frequency, pattern anddifferential diagnosis of echogenic splenic changes: sonographicfollow-up study. Ultraschall Med :151-159, 2000.IF: 0.7

103.
Thiede C, Wündisch T, Alpen B, Neubauer B, Morgner A, SchmitzM, Ehninger G, Stolte M, Bayerdörffer E, Neubauer A: Long termpersistence of monoclonal B-cells after cure of Helicobacter pylori infection and obtaining complete histological remission ingastric mucosa associated lymphoid tissue (MALT) B cell lymphoma.J. Clin. Oncol., 19: 1600-1609, 2001.IF: 7.9

104.
Wieser R, Schreiner U, Wollenberg B, Neubauer A, Fonatsch C,Rieder H: Masked inv (3) (q21Q26) in a patient with minimallydifferentiated acute myeloid leukemia (Correspondence).Haematologica 86: 214-215, 2001.IF: 2.0

105.
Morgner A, Miehlke S, Fischbach W, Schmitt W, Müller-Hermelink HK, Geiner A, Thiede C, Schetelig J, Neubauer A, StolteM, Ehninger G, Bayerdörffer E: Complete remission of primary highgrade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol, 19: 2041-2048, 2001.IF: 7.9

106.
Wittig B, Märten A, Dorbic T, Weineck S, Min H, Nemitz S,Trojaneck B, Flieger D, Kruopis S, Albers A, Löffel J, Neubauer A,Albers P, Müller S, Sauerbruch T, Bieber T, Huhn D, Schmidt-Wolf IGH: Therapeutic vaccination against metastatic carcinoma byexpression-modulated and immunomodified autologous tumor cells: A first clinical phase I/II trial.Human Gene Therapy, 12: 267-278, 2001. IF: 6.4

107.
Thiede C, Bornhäuser M, Oelschlägel U, Brendel C, DaxbergerH, Mohr B, Florek M, Kroschinsky F, Geissler G, Naumann R, RitterM, Prange Krex G, Lion T, Neubauer A, Ehninger G: Sequentialmonitoring of chimerism and detection of minimal residual diseaseafter allogeneic blood stem cell transplantation using multiplexPCR amplification of short tandem repeat markers. Leukemia 15:293-302, 2001.IF: 3.5

108.
Schaich M, Ritter M, Illmer T, Lisske P, Thiede C, Schäkel U,Mohr B, Ehninger G, Neubauer A: Mutations in the ras proto­oncogenes are associated with lower mdr-1 gene expression in adult acute myeloid leukemia. Br J Haematol 112: 300-307, 2001.IF: 3.2

109.
Schmidt M, Hochhaus A, Nitsche A, Hehlmann R, Neubauer A: Expression of nuclear transcription factor interferon consensussequence binding protein in chronic myeloid leukemia correlateswith pretreatment risk features and cytogenetic response tointerferon-alpha. Blood 97: 3648-3650, 2001.IF: 8.7

110.
Reckzeh B, Grebe SO, Rhiele I, Neubauer A, Müller TF:Monitoring of ATG therapy by flow cytometry: comparison of onesingle platform and two different dual platform methods.Transplantation Proceedings 33: 2234-2236, 2001.IF: 0.5

111.
Alpen B, Röbbecke J, Wündisch T, Stolte M, Neubauer A: Helicobacter pylori eradication therapy in gastric high grade nonHodgkin´s lymphoma. Ann Hematology, 80: B106-107, 2001.IF:1.1

112: Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A,Ehninger G, Illmer T: Quantitative determination FLT3 internalrepeat mutations defines a subgroup of poor prognosis inintermediate risk AML. Blood 99: 4326-4335, 2002.IF: 8.7
113.
Liu, H., Ye, H., Ruskone-Fourmestraux, A., De Jong, D., Pileri, S., Thiede, C., Lavergne, A., Boot, H., Caletti, G.,Wündisch, T., Molina, T., Taal, B. G., Elena, S., Thomas, T.,Zinzani, P. L., Neubauer, A., Stolte, M., Hamoudi, R. A., Dogan, A., Isaacson, P. G., Du, M. Q. Liu, H.: t(11;18) is a marker forall stage gastric MALT lymphomas that will not respond to H.pylori eradication. Gastroenterology 122: 1286-1294, 2002.IF:12.1

114.
Jäger, R., List, B., Knabbe, C., Souttou, B., Raulais, D.,Zeiler, T.,Wellstein, A., Aigner, A., Neubauer, A., Zugmaier, G: Serum levels of the angiogenic factor pleiotrophin in relation todisease stage in lung cancer patients. Br J Cancer 86: 858-863, 2002. IF: 3.2

115.
Schaich M, Illmer T, Aulitzky W, Bodenstein H, Clemens M,Neubauer A, Repp R, Schäkel U, Soucek S, Wandt H, Ehninger G:Intensified double induction therapy with high dose mitoxantrone,etoposide, m-amsacrine, and high dose ara-C for patients aged 61­65 years with acute myeloid leukemia. Haematologica 87: 808-817, 2002. IF: 2.0

116.
Ritter M, Mutters R, Schwella N, Beyer J, Wündisch Th,Rüdiger H, von Jan K, Neubauer A: Herstellung vonBlutstammzellprodukten unter Reinraumbedingungen der Klasse A mitHintergrundbedingungen der Klasse B (Teil 1). Pharm Ind 64: 601­606, 2002IF: ­

117.
Ritter M, Mutters R, Schwella N, Beyer J, Wündisch Th,Rüdiger H, von Jan K, Neubauer A: Herstellung vonBlutstammzellprodukten unter Reinraumbedingungen der Klasse A mitHintergrundbedingungen der Klasse B (Teil 2). Pharm Ind 64: 701­707, 2002IF: ­

118.
Johan Vansteenkiste, Robert Pirker, Bartomeu Massuti,Fernando Barata,Albert Font, Michael Fiegl, Salvatore Siena, JenniGateley, Dianne Tomita,Alan B. Colowick, Jaromir Musil, and theAranesp ™ 980297 Study Group (darunter auch A.Neubauer): Doubleblind, placebo controled, randomized phase III trial ofdarbepoetin alpha in lung cancer patients receiving chemotherapy.J Natl Cancer Inst 94: 1211-1220, 2002.IF: 12.9

119.
Schetelig, J., Thiede, C., Bornhauser, M., Schwerdtfeger, R.,Kiehl, M., Beyer, J., Kroger, N., Hensel, M., Scheffold, C., Ho,

A. D., Kienast, J., Neubauer, A., Zander, A. R., Fauser, A. A.,Ehninger, G., Siegert, W.: Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocyticleukemia. Ann Hematol 81 Suppl 2: S47-8, 2002. IF 1.8
120.
Thiede, C, Lutterbeck, K., Oelschlagel, U., Kiehl, M.,Steudel, Ch, Platzbecker, U., Brendel, C., Fauser, A. A., Neubauer, A., Ehninger, G., Bornhauser, M.: Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells.Ann Hematol 81 Suppl 2: S 27-28, 2002.

IF 1.8

121.
Burchert A., Wölfl S, Schmidt M, Brendel C, Denecke B, Cai D,Odyvanova L, Lahaye T, Müller MC, Berg T, Gschaidmeier H, WittigB, Hehlmann R, Hochhaus A, Neubauer A: Interferon -alpha, but notthe ABL kinase inhibitor imatinib induces expression ofmyeloblastin and a sepcific T-cell response in chronic myeloid leukemia. Blood 101: 259 – 64, 2003.IF: 8.7

122.
Kaiser, U., Zugmaier, G., Frank, M., Riedel, I., Neubauer, A., Moll, R.: AFP-producing adenocarcinoma of the stomach. A rare tumor with poor prognosis (Case report). Pathologe 24, 141-145, 2003. IF 0.4

123.
Wündisch T, Neubauer A, Stolte M, Ritter M, Thiede C: B-cell Monoclonality Is Associated With Lymphoid Follicles in Gastritis.Am J Surg Pathol 27: 882-887, 2003.IF: 4,1

124: Schetelig J, Thiede C, Bornhäuser M, Schwerdtfeger R, KiehlM, Beyer J, Sayer HG, Kröger N, Hensel M, Scheffold C, Held TK,Höffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA,Ehninger G, Siegert W: Evidence of a graft versus leukemia effectin chronic lymphocytic leukemia after reduced intensityconditioning and allogeneic stem cell transplantation: Thecooperative German transplant study group. J Clin Oncol 21: 2747­53, 2003.IF: 7.96
125: Alpen B, Wündisch T, Dierlamm J, Börsch G, Stolte M,Neubauer A: Clonal relationship in multifocal non-Hodgkin ’s lymphoma of mucosa-associated lymphoid tissue(MALT). Ann Hematol 83: 124-126, 2004.IF: 1.8
126: Aigner A, Brachmann P, Beyer J, Jäger R, Raulais D, Vigny M,Neubauer A, Heidenreich A, Weinknecht S, F. Czubayko F, Zugmaier
G: Marked increase of the growth factors pleiotrophin andfibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol 14: 1525-1529, 2003.IF: 3.19
127: Müller MC, Gattermann N, Lahaye T, Deininger MWN, Berndt A,Fruehauf S, Neubauer A, Fischer T, Hossfeld DK, Schneller F,Krause SW, Nerl C, Sayer HG, Ottmann OG, Waller C, Aulitzky W. leCoutre P, Freund M, Merx K, Paschka P, König H, Kreil S, Berger U,Gschaidmeier H, Hehlmann R and Hochhaus A: Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous
leukemia patients with imatinib or interferon a/ara-C. Leukemia, 1-9, 2003.IF: 3.5
128: Ritter M, Schwedler J, Beyer J, Movassaghi K, Mutters R,Neubauer A, and Schwella N: Bacterial contamination of ex vivo processed PBPC products under clean room conditions. Transfusion43: 1587-1595, 2003.IF: 3,8
129: Burchert A, Cai D, Hofbauer L, Samuelsson M, Slater EP,Duyster J, Ritter M, Hochhaus A, Müller R, Eilers M, Schmidt M, and Neubauer A: Interferon Consensus Sequence Binding Protein(ICSBP, IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood 103: 3480-89, 2004.IF: 10,3
130: Hofbauer LC, Neubauer A, Schoppet M: DKK1 in multiple myeloma(letter). New Engl J Med 350: 1464-65, 2004. IF: 28
131: Hehlmann, R., Berger, U., Aul, C., Buchner, T., Dohner, H.,Ehninger, G., Ganser, A., Gokbuget, N., Hoelzer, D., Uberla, K.,Gassmann, W., Ludwig, W. D., Rieder, H., Kneba, M., Hochhaus, A.,Reiter, A., Hiddemann, W., Ottmann, O. G., Germing, U., Adelhard, K., Dugas, M., Dirschedl, P., Messerer, D., Bohme, A., Harrison-Neu, E., Griesshammer, M., Kienast, J., Kolb, H. J., Ho, A. D.,Hallek, M., Neubauer, A., Schlegelberger, B., Niederwieser, D., Heil, G., Muller, T., Hasford, J.: The German competence network ‚Acute and chronic leukemias‘. Leukemia 18: 665-669, 2004. IF 4,3
132: Alpen B, Kuse R, Parwaresch R, Müller-Hermelink HK, Stolte M, Neubauer A: Ongoing Monoclonal B-Cell Proliferation Is Not Common in Gastric B-cell Lymphoma After Combined RadiochemotherapyJ Clin Oncol 2004; 22:3039-3045.IF 11,8
133: Ritter M, Kim T, Lisske P, Thiede C, Schaich M, Neubauer A: Prognostic significance of N-ras and K-ras mutations in 232 patients with acute myeloid leukemia (letter). Haematologica 89:1397-99, 2004.IF: 4
134: Görg C, Wollenberg B, Beyer J, Stolte MS, Neubauer A: High­resolution ultrasonography in gastrointestinal graft-versus-host disease. Ann Hematol 84: 33-39, 2005.IF: 1,8
135: Illmer T, Thiede, C., Fredersdorf, A., Stadler, S., Neubauer,A., Ehninger, G., Schaich, M.: Activation of the RAS pathway is
predictive for a chemosensitive phenotype of acute myelogenousleukemia blasts. Clin Cancer Res, 11: 3217-24, 2005
IF: 5,6
136.
Seifart U, Jensen K, Ukena J, Mueller C, Schröder M, FuhrHG, Keppler U, Neubauer A, Staab HJ, Wolf M: Randomized phase IIstudy comparing topotecan cisplatinum administration for 5 daysversus 3 days in the treatment of extensive stage small cell lungcancer (SCLC). Lung cancer 2005; 48: 415-422.IF: 2,9

137.
Stelljes M, Bornhäuser M, Kröger M, Beyer J, Sauerland MC, Heinecke A, Berning B, Scheffold C, Silling G, Büchner T, Neubauer A, Fauser AA, Ehninger G, Berdel W, Kienast J: Conditioning with 8Gy total body irradiation and fludarabine for allogeneichematopoietic stem cell transplantation in acute myeloid leukemia.Blood 106: 3314-21, 2005.

IF: 10,2
138.
Burchert A., Wang Y, Cai D, Bubnoff Nv, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A: Compensatory PI3-Kinase/Akt/mTor activation regulates Imatinib resistance development. Leukemia, 19: 1774-82, 2005.IF: 6,6

139.
Rinn J, Schwella N, Wollmer E, Jaques G, Heinzel-Gutenbrunner M, Strassmann G, Gross MW, Movassaghi K, Neubauer A, Ritter M:Local irradiation prior to stem cell harvest has no influence onCD34+ yield: a quantitative analysis. Ann Hematol 85:38-44, 2006.IF: 1,4

140.
Lenz, G.,Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U.,Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer,H., Martin, S., Heidemann, E., Aldaoud, A., Parwaresch, R.,Hasford, J., Unterhalt, M., Hiddemann, W.: Immunochemotherapy WithRituximab and Cyclophosphamide, Doxorubicin, Vincristine, andPrednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a ProspectiveRandomized Trial of the German Low Grade Lymphoma Study Group (GLSG). J. Clin. Oncol. 23 (9): 1984-1992, 2005.

IF: 11,8
141.
Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H,Ye H, Du M, Kim TD, Bayerdörffer E, Stolte M, Neubauer A: Long­term follow-up of 120 patients with gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 23: 8018-24, 2005 IF: 11,8

142.
Dickhut A, Schwerdtfeger R, Kuklick L, Ritter M, Thiede C, Neubauer A, Brendel C: Mesenchymal stem cells obtained after bonemarrow transplantation or peripheral blood stem cell

transplantation originate from host tissue. Ann Hematol 84: 722­727, 2005.
IF: 1,4
143.
Cai D, Wang Y, Ottmann OG, Barth PJ, Neubauer A, Burchert A: FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment. Blood 107 2094-2097, 2006. IF: 10,2

144.
Ortmann C, Burchert A, Hölzle K, Nitsche A, Wittig B, Neubauer A, Schmidt M: Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylationof CpG motifs in the promoter region. Nucl Acids Res, 33: 6895­6905, 2005IF: 7,2

145.
Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG.: Clinical trial of valproic acid and all­trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 104: 2717-2725, 2005.IF: 4,4

146.
Ritter M, Kattmann D, Teichler S, Hartmann O, Samuelsson MKR,Burchert A, Bach JP, Kim TD, Berwanger B, Thiede C, Jäger R,Ehninger G, Schäfer H, Ueki N, Hayman MJ, Eilers M, Neubauer A: Inhibition of retinoic acid signaling by Ski in acute myeloidleukemia. Leukemia 20: 437-443, 2006.IF: 6,6

147.
Brendel C, Kuklick L., Hartmann O., Kim TD, Boudriot U, Schwell D, Neubauer, A.: Distinct gene expression profile of human mesenchymal stem cells in comparison to skin fibroblasts employingcDNA microarray analysis of 9600 genes. Gene Expression 12: 245­57, 2005.IF: 2,29

148:
Ye H, Gong L, Liu H, Ruskone-Fourmestraux A, de Jong D, Pileri S, Thiede C, Lavergne A, Boot H, Caletti G, Wundisch T, Molina T, Taal BG, Elena S, Neubauer A, Maclennan KA, Siebert R, Remstein ED, Dogan A, Du MQ.: Strong BCL10 nuclear expressionidentifies gastric MALT lymphomas that do not respond to H pylorieradication. Gut 55(1):137-138, 2006. IF 6,6

148:
N Kröger, M Frick, O Gluz, S Mohrmann, B Metzner, ChJackisch, Y. Ko, H Eimermacher, CR Meier, H P Lohrmann, U Ruffert,M Hänel, H Bodenstein, A Neubauer, G Ehninger, HJ Schmoll, K Kolbe, A Hinke, K Mählmann, A R. Zander, U Nitz: Randomized trial of single versus tandem high-dose chemotherapy (STAMP V) followed

by autologous stem cell transplantation in patients withchemosensitive metastatic breast cancer. J Clin Oncol 2006, 24:3919­
IF: 11,8
149: Sohlbach K, Heinze S, Shiratori K, Sure U, Pagenstecher A, Neubauer A: Encephalopathy In A Patient After Long-Term Treatment With Thalidomide (Case report). J Clin Oncol, 24: 4942-44, 2006IF: 11,8
150: Mandic R, Rodgarkia-Dara CJ, Zhu L, Folz BJ, Bette M, Weihe E, Neubauer A, Werner JA. Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux®) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS Lett. 2006,580: 4793-4800. IF 3,4
151: Dunne J, Cullmann C, Ritter M, Soria NM, Drescher B, Debernardi S, Skoulakis S, Hartmann O, Krause M, Krauter J, Neubauer A, Young BD, Heidenreich O. siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts. Oncogene. 2006; 25: 6067-78 IF: 6,87
152: Wilhelm C, Neubauer A, Brendel C: Discordant results of flow cytometric ZAP-70 expression status in B-CLL samples if different gating strategies are applied. Cytometry B, Clin Cytometry70B(4):242-250, 2006. IF: 1,7
153: Bach JP, Kiessling AM, Kleinhans A, Faoro C, Gorg C, Riera-Knorrenschild J, Schwella N, Wagner HJ, Neubauer A: Pulmonaryfibrosis in a patient treated with erlotinib (Case report).Onkologie 29(7):342-3, 2006.IF: 1,2
154.
Wündisch T, Mösch C, Neubauer A, Stolte M: Helicobacterpylori eradication in gastric mucosa associated lymphoid tissuelymphoma: Results of a 196-case series. Leuk Lymphoma 47: 2110-14, 2006 IF: 1,29

155.
Mey, U.J.M., Orlopp, K.S., Flieger, D., Strehl, J.W., Ho, A.D., Hensel, M., Bopp, C., Gorschlüter, M., Wilhelm, M., Birkmann, J.,Kaiser, U., Neubauer, A., Florschütz, A., Rabe, Chr., Hahn, C.,Glasmacher, A. und Schmidt-Wolf I.G.H.: Dexamethasone, High-Dose Cytarabine, and Cisplatin in Combination with Rituximab as SalvageTreatment for Patients with Relapsed or Refractory Aggressive Non­Hodgkin`s Lymphoma. Cancer Investigation, 24: 593-600, 2006.

IF: 1,84

156.
Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, and Burchert A: Adaptive secretion of theGranulocyte Macrophage Colony Stimulating Factor (GM-CSF) mediates Imatinib-and Nilotinib-resistance in BCR/ABL-positive progenitors via JAK-2/STAT-5 pathway activation. Blood, 2007; 109:2147-55. IF: 10,1

157.
Brendel C, Scharenberg C, Gessner M, Robey R, Burchert A, Hoffmann J, Boudriot U, Jaques G, Neubauer A: Imatinib mesylateand nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia, 21: 1267­75, 2007.IF: 6,6

158.
Dror N, Rave-Harel N, Burchert A, Azriel A, Tamura T, Tailor P, Neubauer A, Ozato K, Levi BZ: Interferon Regulatory Factor-8 Is Indispensable for the Expression of Promyelocytic Leukemia and theFormation of Nuclear Bodies in Myeloid Cells. J Biol Chem 2007;282: 5633–5640. IF: 5,8

159.
Kreutzer M, Fauti T, Kaddatz K, Seifart C, Neubauer A, Schweer H, Kömhoff M, Müller-Brüsselbach S, Müller R: Specificcomponents of prostanoid-signaling pathways are present in non­small cell lung cancer cells. Oncology Rep, 18: 497-501, 2007IF: 1,5

160.
Mack E, Neubauer A, Brendel C: Comparison of RNA yield from small cell populations sorted by flow cytometry applying differentisolation procedures. Cytometry A, 71A, 404-409, 2007.IF: 2,1

161: Herold, M., Haas, A., Srock, S., Neser, S., Al-Ali, K. H., Neubauer, A., Dolken, G., Naumann, R., Knauf, W., Freund, M.,Rohrberg, R., Hoffken, K., Franke, A., Ittel, T., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Assmann, M., von Grunhagen,U.: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenanceprolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J ClinOncol 25: 1986-92, 2007.IF: 13,6
162: Srock, S., Schriever, F., Neubauer, A., Herold, M., Huhn, D.:Long-term treatment with rituximab is feasible in selected patients with B-CLL: Response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy.
Leukemia and Lymphoma 48: 905-911, 2007.
IF: 1,93
163: Fischbach W, Goebeler ME, Ruskone-Fourmestraux A, Wündisch T,Neubauer A, Savio A, Raderer M: Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be safely managed by a watch­and-wait strategy. Experience from a large international series. Gut, 56: 1685-87, 2007.
IF: 9,7
164. Hagenah GC, Wündisch T, Eckstein E, Zimmermann S, Holst F,Grimm W, Neubauer A, Lohoff M: Sepsis-like disease in an immunocompromised patient with travel history to Mallorca (Casereport). Internist 48:727-730, 2007. IF: 0,27
165: Mikesch J., Burchert A., Kress O., Ritter M., Görg C.,Neubauer A.: Diffuse pneumatosis due to central venouscatherization in a patient with acute graft versus host disease.Ann Hematol 86: 767-69, 2007 (Letter). IF: 2,2
166: Neubauer A, Maharry K, Mrózek K, Thiede C, Marcucci G, Paschka P, Mayer RJ, Larson RA, Liu ET, and Bloomfield CD: Patients with acute myeloid leukemia and RAS mutations benefit most from postremission treatment with high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol 26: 4603-09, 2008.IF 17,1
167: Schulz S, Häussler U, Mandic R, Heverhagen JT, Neubauer A, Dünne AA, Werner JA, Weihe E, and Bette M: Treatment with ozone/oxygen-pneumoperitoneum results in complete remission of rabbit squamous cell carcinomas. Int J Cancer 122: 2360-67, 2008.IF 4,73
168: Huynh M, Wacker HH, Wündisch T, Sohlbach K, Kim TD, Krause M,Stabla K, Roth P, Fischbach W, Stolte M, Neubauer A: Expressionprofiling reveals specific gene expression signatures in gastricMALT lymphomas. Leuk Lymphoma 49: 974-983, 2008.IF: 1,93
169: Teichler S, Schlenk RF, Strauch K, Hagner N, Ritter M, Neubauer
A: Expression of the nuclear oncogene Ski in patients with acute myeloid leukemia treated with all-trans retinoic acid. Haematologica, 93(7): 1105-7, 2008. IF: 5,97
170: Knoll S, Zimmer S, Hinney A, Scherag A, Neubauer A, Hebebrand
J: Val103Ile polymorphism of the melanocortin-4 receptor gene (MC4R) in cancer cachexia. BMC Cancer, March 31; 8:85, 1-7, 2008.
IF: 3,08
171: Neeße A, Kalinowski M, Walthers EM, Görg C; Neubauer A: Clinical management of massive retroperitoneal hemorrhage afterbone marrow biopsy (Case report). Leuk Lymphoma 50: 475-77, 2009. IF: 1,93
172: Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S,Chaturvedi A, Eilers M, Engehofer E, Neubauer A, Burchert A:Compassionate-use of sorafenib in Flt3-ITD positive acute myeloid leukemia: sustained regression prior and post allogenic stem celltransplantation. Blood 2009; 113: 6567-6571.IF: 10,89
173: Huynh MQ, Barth P, Sohlbach K, Neubauer A, Görg C: B-mode ultrasound and contrast-enhanced ultrasound pattern of focal extramedullary hematopoiesis in the spleen in a patient withmyeloproliferative disease (Case report). Ultraschall Med, 30:297-99, 2009.IF: 1,64
174: Krüger A, Hamann C, Brendel C, Ramaswamy A, Schnabel M,Neubauer A, Hofbauer LC: Multimodal therapy for vertebralinvolvement of systemic mastocytosis (Case report). Spine 34: E626-628, 2009, IF: 2,79
175: Metzelder SK, Reinke C, Walthers EM, Barth P, Vogelmeier C,Neubauer A, Bals R: Malignant ARDS. Internist 50: 1274 – 77, 2009. IF: 0,27
176: Meyer M, Rübsamen D, Slany R, Illmer T, Stabla K, Roth P, Stiewe S, Eilers M, Neubauer A: Oncogenic RAS enables DNA damage­and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. PLoS One 4(11): e7768, 2009. IF: 4.351
177.
Burchert A, Müller M, Kostrewa P, Erben P, Bostel T, Liebler S, Hehlmann R, Neubauer A, Hochhaus A: Improved molecular remission with Interferon alpha (IFN) Maintenance Therapy afterInduction with Imatinib plus IFN in Patients with Chronic MyeloidLeukemia. J Clin Oncol, 28: 1429-1435, 2010. IF: 17,1

178.
Lorch, A., Neubauer, A., Hackenthal, M., Dieing, A., Hartmann, J. T., Rick, O., Bokemeyer, C., Beyer, J.: High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Ann Oncol 2010; 21: 820-825. IF: 5,3

179.
Craig V, Arnold I, Gerke C, Huynh MQ, Wündisch T, Neubauer A,Renner C, Falkow S, Mueller A: Gastric MALT lymphoma B-cells express polyreactive, somatically mutated immunoglobulins. Blood 115: 581 – 591, 2010IF: 10,4

180.
Cyrus Khandanpour, Christian Thiede, Peter J.M. Valk, Ehssan Sharif-Askari, Holger Nückel, Dietmar Lohmann, Bernhard Horsthemke, Winfried Siffert, Andreas Neubauer, Karl-Heinz Grzeschik, Clara D. Bloomfield, Guido Marcucci, Kati Maharry,Marilyn L. Slovak, Bert A. van der Reijden, Joop H. Jansen, Hans

K. Schackert, Khashayar Afshar, Susanne Schnittger, Justine K.Peeters, Frank Kroschinsky, Gerhard Ehninger, Bob Lowenberg, Ulrich Dührsen, and Tarik Möröy: A variant allele of growth factor independence 1 is associated with acute myeloid leukemia. Blood 115: 2462-2472, 2010 IF: 10,4
181. Meyer T, Ruppert V, Görg C, Neubauer A: Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietictissuein a polycythemia vera patient. A case report. Int J Hematol91:117-20, 2010 IF: 1,3
182: Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T,Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE:Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib and dasatinib.Drug Metabolism and Disposition, 2010, 38: 1371-1380.IF: 3,8
183: Görg C, Bert T, Klassen E, Neesse A, Barth P, Neubauer A: Kontrastunterstützte sonografische Befunde beihepatischer Candidiasis. Z Gastroenterol 2010, 48: 678-82. IF: 0,88
184: Metzelder S, Wollmer E, Neubauer A, Burchert A: Sorafenib bei rezidivierter und therapierefraktärer FLT3-ITD-positiver akuter myeloischer Leukämie: eine neue Behandlungsoption. Dtsch Med Wschr 2010; 135: 1852-1856.IF: 0,59
185: Teichler S, Illmer T, Roemhild J, Ovcharenke D, Stiewe T,Neubauer A: MicroRNA29a regulates the expression of the nuclearoncogene Ski. Blood 2011; 118: 1899-1902.IF: 10,55
186: Wilhelm C, Neubauer A, Burchert A: Poor risk cytogenetics may be associated with inferior outcome after FLAMSA-reduced intensity conditioning in high-risk AML patients (scientific letter). Leuk Lymphoma 2011; 52: 2031-35.
IF: 2,39
187: Hartz B, Volkmann Th, Irle S., Loechelt C, Neubauer A, Brendel C: a4 integrin levels on mobilized peripheral blood stemcells predict rapidity of engraftment in patients receiving
autologous stem cell transplantation Blood 2011; 118: 2362-2365.IF: 10,55
188: Schmitt M, Neubauer A, Greiner J, Xu X, Barth TFE, Bechter K:Spreading of Acute Myeloid Leukemia Cells by Trafficking along the Peripheral Outflow Pathway of Cerebrospinal Fluid (Case report).Anticancer Res 2011; 31: 2343-2346. IF: 1,65
189: Alice Fabarius, Armin Leitner, Andreas Hochhaus, Martin C. Müller, Benjamin Hanfstein, Claudia Haferlach, Gudrun Göhring, Brigitte Schlegelberger, Martine Jotterand, Andreas Reiter,Susanne Jung-Munkwitz, Ulrike Proetel, Juliana Schwaab, Wolf-Karsten Hofmann, Jörg Schubert, Hermann Einsele, Anthony D. Ho, Christiane Falge, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller,Karsten Spiekermann, Gabriela M. Baerlocher, Michael Lauseker,Markus Pfirrmann, Joerg Hasford, Susanne Saussele, and Rüdiger Hehlmann for the Schweizerische Arbeitsgemeinschaft für KlinischeKrebsforschung (SAKK) and the German CML Group: Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 6760-68.IF: 10,55
190: Ashu Kumari, Cornelia Brendel, Andreas Hochhaus, Andreas Neubauer, Andreas Burchert: Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 2012; 119: 530-539.IF: 10,55
191:
Metzelder, S. K., Schroeder, T., Finck, A., Scholl, S., Fey,M., Gotze, K., Linn, Y. C., Kroger, M., Reiter, A., Salih, H. R.,Heinicke, T., Stuhlmann, R., Muller, L., Giagounidis, A., Meyer,

R.
G., Brugger, W., Vohringer, M., Dreger, P., Mori, M., Basara,N., Schafer-Eckart, K., Schultheis, B., Baldus, C., Neubauer, A.,Burchert, A.: High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 2012, 26, 2353–2359. IF: 8,96

192: Thomas Wündisch, Philipp Dieckhoff, Brandon Greene, Christian Thiede, Christian Wilhelm, Manfred Stolte and Andreas Neubauer: A 10-year Follow-up of 120 Patients with Gastric MALT Lymphoma after Helicobacter pylori Eradication. Gastroenterology 2012, 143:936­42.
IF: 12,03
193: Philipp Nold; Cornelia Brendel; Andreas Neubauer; Gregor Bein; Holger Hackstein: Good manufacturing practice-compliant animal-free expansion of human bone marrow derived mesenchymal stroma cells in a closed hollow-fiber-based bioreactor. Biochemical and Biophysical Research Communications 2013, 430: 325-330. IF: 2,53
194: Bornhäuser M, Kienast J, Trenschel R, Burchert A, HegenbartU, Stadler M, Baurmann H, Schäfer-Eckart K, Holler E, Kröger N, Schmid C, Einsele H, Kiehl MG, Hiddemann W, Schwerdtfeger R,Buchholz S, Dreger P, Neubauer A, Berdel WE, Ehninger G, Beelen DW, Schetelig J, Stelljes M.: Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic celltransplantation in patients with acute myeloid leukaemia in firstcomplete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncology 2012, Oct 13 (10): 1035-1044.IF: 22,58
195: Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M,Fabarius A, Schnittger S, Haferlach C, Göhring G, Proetel U, KolbHJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, HänelM, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K,Baerlocher GM, Pfirrmann M, Hasford J, Saußele S, Hochhaus A;SAKK; German CML Study Group: Early molecular and cytogeneticresponse is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012,26: 2096-2102. IF: 8,96
196: Sohlbach K, Moll R, Goßmann J, Nowak O, Barth P, Neubauer A,Huynh MQ: ß-Catenin signaling: no relevance in Hodgkin lymphoma? Leukemia Lymphoma 2012, 53: 996-998.IF: 2,58
197: Brigitte Mohr, Johannes Schetelig, Kerstin Schäfer-Eckart,Norbert Schmitz, Mathias Hänel, Wolf Rösler, Norbert Frickhofen,Hartmut Link, Andreas Neubauer, Ulrich Schuler, Uwe Platzbecker,Jan M. Middeke, Gerhard Ehninger, Martin Bornhäuser, Markus Schaich, Friedrich Stölzel and on behalf of the Study Alliance Leukaemia (SAL): Impact of allogeneic haematopoietic stem celltransplantation in patients with abnl(17p) acute myeloidleukaemia. Br J Haematol 2013; 161: 237-244.IF: 4,9
198: Markus Schaich, Stefani Parmentier, Michael Kramer, Thomas Illmer, Friedrich Stölzel, Christoph Röllig, Christian Thiede,
Mathias Hänel, Kerstin Schäfer-Eckart, Walter Aulitzky, Hermann Einsele, Anthony D. Ho, Hubert Serve, Wolfgang E. Berdel, Jiri Mayer, Norbert Schmitz, Stefan W. Krause, Andreas Neubauer, Claudia D. Baldus, Johannes Schetelig, Martin Bornhäuser, andGerhard Ehninger : High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute MyeloidLeukemia: Results of the Prospective Randomized AML2003 Trial. JClin Oncol 2013; 31: 2094-2102. IF: 18
199.
Hubert Serve, Utz Krug, Ruth Wagner, M. Cristina Sauerland, Achim Heinecke, Uta Brunnberg,.Markus Schaich, Oliver Ottmann,Justus Duyster, Hannes Wandt, Thomas Fischer, AristotelesGiagounidis, Andreas Neubauer, Albrecht Reichle, Walter Aulitzky, Richard Noppeney, Igor Blau, Volker Kunzmann, Reingard Stuhlmann,Alwin Kramer, Karl-Anton Kreuzer, Christian Brandts, Bjorn Steffen, Christian Thiede, Carsten Muller-Tidow, Gerhard Ehninger, and Wolfgang E. Berdel.Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia:Results From a Randomized, Placebo-Controlled Trial. J Clin Oncol

2013; 31: 3110-3117.IF: 18

200.
Rüdiger Hehlmann, Martin C. Müller, Michael Lauseker,Benjamin Hanfstein, Alice Fabarius, Annette Schreiber, UlrikeProetel, Nadine Pletsch, Markus Pfirrmann, Claudia Haferlach,Susanne Schnittger, Hermann Einsele, Jolanta Dengler, ChristianeFalge, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, KarstenSpiekermann, Gabriela M. Baerlocher, Gerhard Ehninger, DominikHeim, Hermann Heimpel, Christoph Nerl, Stefan W. Krause, Dieter K.Hossfeld, Hans-Jochem Kolb, Joerg Hasford, Susanne Saußele, and Andreas Hochhaus: Deep Molecular Response (MR4.5) is reached bythe majority of imatinib-treated patients, predicts survival, and is achieved faster by optimized high-dose imatinib-results from the randomized CML-Study IV. J Clin Oncol; 32: 415-423.IF: 18

201.
Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller MC, Hanfstein B, Schreiber A, Fabarius A, Pfirrmann M, Schnittger S,Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Krause SW, Heim D, Nerl C, HossfeldDK, Kolb HJ, Hochhaus A, Hasford J, Hehlmann R; German ChronicMyeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaftfür Klinische Krebsforschung (SAKK): Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators:results from the randomized CML study IV. Ann Hematol 2014; 93: 71-80. IF: 2,86

202.
Benjamin Hanfstein, Valeria Shlyakhto, Michael Lauseker,Rüdiger Hehlmann, Susanne Saussele, Christian Dietz, PhilippErben, Alice Fabarius, Ulrike Proetel, Susanne Schnittger, StefanKrause, Joerg Schubert, Hermann Einsele, Mathias Haenel, JolantaDengler, Christina Falge, L. Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius Waller,Karsten Spiekermann, Gabriela Baerlocher, Markus Pfirrmann, Joerg Hasford, Wolf-Karsten Hofmann, Andreas Hochhaus, and Martin Mueller: Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML)patients in chronic phase on treatment with imatinib. Leukemia, in the press 2014.IF: 10,16

203.
Tonigold M, Rossmann A, Meinold M, Bette M, Märken M,Henkenius K, Bretz AC, Giel G, Cai C, Rodepeter FR, Beneš V,Grénman R, Carey TE, Lage H, Stiewe T, Neubauer A, Werner JA,Brendel C, Mandic R. „A cisplatin resistant head and neck cancercell line with cytoplasmic p53mut exhibits ATP -binding cassettetransporter up-regulation and high glutathione levels“, Journal of Cancer Research and Clinical Oncology, in press 2014IF: 2,914

204.
Minh Huynh, Jennifer Goßmann, Stefan Gattenlöhner, Wolfram Klapper, Hans-Heinrich Wacker, Annette Ramaswamy, Alwina Bittner, Ulrich Kaiser & Andreas Neubauer: Expression and pro-survival function of phospholipase Cg2 in diffuse large B-cell lymphoma. Leukemia and Lymphoma 2014; ePub Sep 8: 1-8.IF: 2,605

205.
Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P,Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, KrauseSW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L,Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK,Hochhaus A, Müller MC, SAKK and the German CML Study Group:Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.Haematologica. 2014 Sep; 99 (9):1441-7. doi:10.3324/haematol.2013.096537. Epub 2014 May 16.IF: 5,868

206.
Hoffmann JC, Stabla K, Burchert A, Volkmann T, Bornhäuser M,Thiede C, Neubauer A, Brendel C: Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantationemploying semi-automated CD34+ donor cell chimerism analysis. Ann Hematol. 2014 Feb; 93(2):279-85. doi: 10.1007/s00277-013-1961-4. Epub 2013 Dec 19.IF: 2,396

207.
Johannes Schetelig, Markus Schaich, Kerstin Schaefer-Eckhardt, Mathias Haenel, Walter AULITZKY, Hermann Einsele,Norbert Schmitz, Wolf Rösler, Matthias Stelljes, Claudia Baldus,Anthony Ho, Andreas Neubauer, Hubert Serve, Jiri Mayer, Wolfgang Berdel, Brigitte Mohr, Uta Oelschlägel, Stefani Parmentier,Christoph Roellig, Michael Kramer, Uwe Platzbecker, Thomas Illmer,Christian Thiede, Martin Bornhäuser, and Gerhard Ehninger:Hematopoietic Cell Transplantation in Patients with intermediate and high-risk AML -Results from the Randomized Study AllianceLeukemia (SAL) AML 2003 Trial. Leukemia 2015; 29: 1060-1068. IF: 10,43

208.
PHILIPP NOLD, HOLGER HACKSTEIN, TABEA RIEDLINGER,.CORNELIA KASPER, ANNE NEUMANN, MARCO MERNBERGER,.CHRISTIAN FÖLSCH, JANSCHMITT, SUSANNE FUCHS-WINKELMANN, CHRISTINA BARCKHAUSEN, MADELEINE KILLER, ANDREAS NEUBAUER & CORNELIA BRENDEL: Immunosuppressive capabilities of mesenchymal stromal cells aremaintained under hypoxic growth conditions and after gamma

irradiation. Cytotherapy, 17: 152-162. IF: 3,509

209.
Fariba Fouladi, Lutz B. Jehn, Stephan K. Metzelder, FlorianHub, Katharina Henkenius, Andreas Burchert, Cornelia Brendel,Thorsten Stiewe, and Andreas Neubauer: Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation. Leukemia and Lymphoma 2015; 56(9):2690-8.IF: 2,605

210.
Andreas Burchert, Susanne Saussele, Ekkehard Eigendorff,Martin Mueller, Kristina Sohlbach, Sabrina Inselmann, ChristinSchütz, Stephan Metzelder, Janine Ziermann, Philippe Kostrewa,Jörg Hoffmann, Rüdiger Hehlmann, Andreas Neubauer, and Andreas Hochhaus: Interferon alpha 2 (IFN) maintenance therapy may enablehigh rates of treatment discontinuation in chronic myeloid leukemia (CML). Leukemia 2015; 29:1331-1335. IF: 10,43

211.
Lida Kalmanti, Susanne Saussele, Michael Lauseker, MartinMueller, Christian Dietz, Lisa Heinrich, Benjamin Hanfstein,Ulrike Proetel, Alice FABARIUS, Stefan Krause, SébastienRinaldetti, Jolanta Dengler, Christina Falge, Elisabeth OppligerLeibundgut, Andreas Burchert, Andreas Neubauer, Lothar Kanz, Frank Stegelmann, Michael Pfreundschuh, Karsten Spiekermann, ChristophScheid, Markus Pfirrmann, Andreas Hochhaus, Jörg Hasford, and Rüdiger Hehlmann: SAFETY AND EFFICACY OF IMATINIB IN CML OVER APERIOD OF 10 YEARS: DATA FROM THE RANDOMIZED CML-STUDY IV. Leukemia 2015; 29:1123-1132.IF: 10,43

212.
Cornelia Brendel, Sabine Teichler, Axel Millahn, Thorsten Stiewe, Michael Krause, Kathleen Stabla, Petra Ross, Minh Huynh,Thomas Illmer, Marco Mernberger, Christina Barckhausen and Andreas Neubauer: Oncogenic NRAS primes primary acute myeloid leukemiacells for differentiation. PLoS One 2015; 10(4): e0123181 IF: 3,53

213.
Stephan Metzelder, Christian Michel, Malte von Bonin, MiriamRehberger, Elisabeth Hessmann, Sabrina Inselmann, Maria Solovey,Ying Wang, Kristina Sohlbach, Cornelia Brendel, Thorsten Stiewe, Joel Charles, Andre Ten Haaf, Volker Ellenrieder, Andreas Neubauer, Stefan Gattenlöhner, Martin Bornhäuser, and AndreasBurchert: NFATc1 as a therapeutic target in FLT3-ITD-positive AML. Leukemia 2015; 29: 1470-1477.IF: 10,43

214.
Robert Zeiser, Andreas Burchert, Claudia Lengerke, MareikeVerbeek, Kristina Maas-Bauer, Stephan Metzelder, Silvia Spoerl, Markus Ditschkowski, Matyas Ecsedi, Katja Sockel, Francis Ayuk,Salem Ajib, Flore Sicre de Fontbrune, Il-Kang Na, Livius Penter,Udo Holtick, Dominik Wolf, Esther Schuler, Everett Meyer, PetyaApostolova, Hartmut Bertz, Reinhard Marks, Michael Lübbert, RalphWäsch, Christof Scheid, Friedrich Stölzel, Rainer Ordemann, GesineBug, Guido Kobbe, Rob Negrin, Mats Brune, Alexandros Spyridonidis, Annette Schmitt-Gräff, Walter van der Velden, Gerwin Huls, Stephan Mielke, Götz Ulrich Grigoleit, Jürgen Kuball, Ryan Flynn, GabrieleIhorst, Jing Du, Bruce Blazar, Renate Arnold, Nicolaus Kröger,

Jakob Passweg, Joerg Halter, Gérard.Socié, Dietrich Beelen, Christian Peschel, Andreas Neubauer, Jürgen Finke, Justus Duyster, and Nikolas von Bubnoff: Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multi-center survey. Leukemia 2015, 29(10):2062-8IF: 10,43

215.
F Stölzel, B Mohr, M Kramer, U Oelschlägel, T Bochtler, WEBerdel, M Kaufmann, CD Baldus, K Schäfer-Eckart, R Stuhlmann, H Einsele, SW Krause, H Serve, M Hänel, R Herbst, A Neubauer, KSohlbach, J Mayer, JM Middeke, U Platzbecker, M Schaich, A Krämer, C Röllig, J Schetelig, M Bornhäuser and G Ehninger: Karyotype complexity and prognosis in acute myeloid leukemia. Blood Cancer J2016, 6, e386; doi:10.1038/bcj.2015.114.IF: 3,46

216.
Jennifer Goßmann, Manfred Stolte, Michael Lohoff, Philipp Yu, Roland Moll, Florian Finkernagel, Holger Garn, Cornelia Brendel,Alwina Bittner, Andreas Neubauer, Minh Q. Huynh: A gain-of­function mutation in the Plcg2 gene protects mice fromHelicobacter felis-induced gastric MALT lymphoma. PLoS ONE 2016, 11(3): e0150411.

IF: 3,23

217.
Christoph Röllig, Hubert Serve, Andreas Hüttmann, RichardNoppeney, Carsten Müller-Tidow, Utz Krug, Claudia D Baldus, Christian H Brandts, Volker Kunzmann, Hermann Einsele, AlwinKrämer, Kerstin Schäfer-Eckart, Andreas Neubauer, Andreas

Burchert, Aristoteles Giagounidis,.Stefan W Krause, AndreasMackensen, Walter Aulitzky, Regina Herbst, Mathias Hänel,Alexander Kiani, Norbert Frickhofen, Johannes Kullmer, UlrichKaiser, Hartmut Link, Thomas Geer, Albert Reichle, ChristianJunghanß, Roland Repp, Frank Heits, Heinz Dürk, Jana Hase, Ina-Maria Klut, Thomas Illmer, Martin Bornhäuser, Markus Schaich, Stefani Parmentier, Martin Görner, Christian Thiede, Malte vonBonin, Johannes Schetelig, Michael Kramer, Wolfgang E Berdel,Gerhard Ehninger, for the Study Alliance Leukaemia: Addition of sorafenib versus placebo to standard therapy in patients aged 60years or younger with newly diagnosed acute myeloid leukaemia(SORAML): a multicentre, phase 2, randomised controlled trial.Lancet Oncology 2015; 16: 1691-1699. IF: 24,69

218.
C Müller-Tidow, P Tschanter, C Röllig, C Thiede, A Koschmieder, M Stelljes, S Koschmieder, M Dugas, J Gerss,.T Butterfaß-Bahloul, R Wagner, M Eveslage, U Thiem, SW Krause, U

Kaiser, V Kunzmann, B Steffen, R Noppeney, W Herr, CD Baldus, NSchmitz, K Götze, A Reichle, M Kaufmann, A Neubauer, K Schäfer-Eckart, M Hänel, R Peceny,.N Frickhofen, M Kiehl, A Giagounidis, M
Görner, R Repp, H Link, A Kiani, R Naumann, TH Brümmendorf, HServe, G Ehninger, WE Berdel and U Krug for the Study AllianceLeukemia Group: Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloidleukemia: The AML-AZA trial of the study alliance leukemia. Leukemia 2016; 30: 555-561.IF: 10,431
219.
Elias K. Mai, Axel Benner, Uta Bertsch, Peter Brossart,Annette Hänel, Volker Kunzmann, Ralph Naumann, Kai Neben, GerlindeEgerer, Anthony D. Ho, Jens Hillengass, Marc S. Raab, Andreas Neubauer, Astrid Peyn, Yon-Dschun Ko, Norma Peter, Christof Scheid and Hartmut Goldschmidt: Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiplemyeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol, 2016, 173: 731-741.IF: 5,4

220.
Mack E, Stabla K, Riera-Knorrenschild J, Moll R, Neubauer A,Brendel C: A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis andpyrosequencing. BMC Cancer 2016; Aug 2, 16:585. doi: 10.1186/s12885-016-2589-2

IF: 3,26

221.
Christin Schütz, Sabrina Inselmann, Susanne Saussele,Christian T. Dietz, Martin Müller, Ekkehard Eigendorff, Cornelia

A. Brendel, Tim H. Brümmendorf, Cornelius Waller, Jolanta Dengler,Maria Elisabeth Goebeler, Regina Herbst, Gernot Freunek, StefanHanzel1, Thomas Illmer, Ying Wang, Thoralf Lange, Florian Finkernagel, Rüdiger Hehlmann, Andreas Neubauer, Andreas Hochhaus, Markus Pfirrmann, Joelle Guilhot, Francois Xavier Mahon, andAndreas Burchert: Prediction of molecular relapse after treatmentdiscontinuation in chronic myeloid leukemia. Leukemia 2017, 31: 829-836. IF: 12,104
222. Albring JC, Inselmann S, Sauer T, Schliemann C, Altvater B,Kailayangiri S, Rössig C, Hartmann W, Knorrenschild JR, SohlbachK, Groth C, Lohoff M, Neubauer A, Berdel WE, Burchert A, Stelljes
M: PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation. Bone Marrow Transplantation 2017; 52: 317-320 IF: 3,636
223.
Miriam Frech, Lutz B. Jehn, Kathleen Stabla, Stephan Mielke,Björn Steffen, Hermann Einsele, Stephan K. Metzelder, and Andreas Neubauer: Dasatinib and allogeneic stem cell transplantationenable sustained response in an elderly patient with RCSD1-ABL1­positive acute lymphoblastic leukemia. Haematologica, 2017, 102: e160-e162. IF: 9,090

224.
Schoffer, O., Schulein, S., Arand, G., Arnholdt, H., Baaske,D., Bargou, R. C., Becker, N., Beckmann, M. W., Bodack, Y., Bohme,B., Bozkurt, T., Breitsprecher, R., Buchali, A., Burger, E.,Burger, U., Dommisch, K., Elsner, G., Fernschild, K., Flintzer, U., Funke, U., Gerken, M., Gobel, H., Grobe, N., Gumpp, V.,Heinzerling, L., Kempfer, L. R., Kiani, A., Klinkhammer-Schalke, M., Klocking, S., Kreibich, U., Knabner, K., Kuhn, P., Lutze,S.,Mader, U., Maisel, T., Maschke, J., Middeke, M., Neubauer, A.,Niedostatek, A., Opazo-Saez, A., Peters, C., Schell, B., Schenkirsch, G., Schmalenberg, H., Schmidt, P., Schneider, C.,Schubotz, B., Seide, A. Strecker, P. Taubenheim, S., Wackes, M.,Weiss, S., Welke, C., Werner, C., Wittekind, C., Wulff, J., Zettl,H., Klug, S. J.: Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011. BMC Cancer 2016; 16: 936IF: 3,26

225.
Alexander E. Perl; Jessica K. Altman; Jorge Cortes; Catherine Smith; Mark Litzow; Maria R. Baer; David Claxton; Harry P. Erba;Stan Gill; Stuart Goldberg; Joseph Jurcic; Richard A. Larson;Chaofeng Liu; Ellen Ritchie; Gary Schiller; Alexander Spira;Stephen Strickland; Raoul Tibes; Celalettin Ustun; Eunice S. Wang;

Robert Stuart; Christoph Röllig; Andreas Neubauer; Giovanni Martinelli; Erkut Bahceci; Mark Levis: Selective Inhibition of FLT3 by Gilteritinib, in Relapsed/Refractory Acute MyeloidLeukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study. Lancet Oncology 2017, 18: 1061-1075. IF: 26,509

226.
Madeleine C. Killer, Philipp Nold, Katharina Henkenius, Lea Fritz, Tabea Riedlinger, Christina Barckhausen, Miriam Frech,Holger Hackstein, Andreas Neubauer and Cornelia Brendel: Immunosuppressive capacity of mesenchymal stem cells correlateswith metabolic activity and can be enhanced by valproic acid. Stem cell research and therapy 2017; 8(1):100. IF: 4,504

227.
Rüdiger Hehlmann, Michael Lauseker, Susanne Saussele, Markus Pfirrmann, Stefan Krause, Hans-Jochem Kolb, Andreas Neubauer,Dieter Hossfeld, Christoph Nerl, Alois Gratwohl, GabrielaBaerlocher, Dominik Heim, T.H. Brümmendorf, Alice FABARIUS,Claudia Haferlach, Brigitte Schlegelberger, Martin Müller, SabineJeromin, Ulrike Proetel, Katharina Kohlbrenner, Astghik Voskanyan,Sébastien Rinaldetti, Wolfgang SEIFARTH, B Spieß, Leopold Balleisen, Maria Goebeler, Mathias Hänel, Anthony Ho, JolantaDengler, Christina Falge, L. Kanz, Stephan Kremers, Andreas Burchert, Michael Kneba, Frank Stegelmann, Claus-Henning Köhne, Hans-Walter Lindemann, Cornelius Waller, Michael Pfreundschuh, Karsten Spiekermann, Wolfgang Berdel, Lothar Müller, MatthiasEdinger, Jiri Mayer, Dietrich Beelen, Martin Bentz, Hartmut Link, Bernd Hertenstein, R Fuchs, Martin Wernli, F Schlegel, RudolfSchlag, Maike de Wit, Lorenz Truemper, Holger Hebart, Markus Hahn,Jörg Thomalla, Christoph Scheid, Philippe Schafhausen, WalterVerbeek, Michael Eckart, Winfried Gassmann, Antonio Pezzutto, Michael Schenk, Peter BROSSART, Thomas Geer, Stephan Bildat,Erhardt Schäfer, Andreas Hochhaus, and Joerg Hasford: Assessmentof imatinib as first-line treatment of chronic myeloid leukemia: 10–year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 2017, 31: 2398-2406. IF: 11,7

228.
Katharina Henkenius, Brandon H Greene, Christina Barckhausen,Raimo Hartmann, Melanie Märken, Tom Kaiser, Miriam Rehberger, Stephan K Metzelder, Wolfgang J Parak, Andreas Neubauer, Cornelia Brendel, Elisabeth Mack: Maintenance of cellular respiration indicates drug resistance in acute myeloid leukemia. Leukemia Research 2017; 62: 56-63IF: 2,501

229.
Herwig Strik, Ursula Keber, Wasim Alhaj Hammoud, Jorge Riera-Knorrenschild, Barbara Carl, Richard Dodel, Axel Pagenstecher, Andreas Neubauer: Immune checkpoint inhibitore associated CNS autoimmune disorder (ICICAD) following nivolumab treatment: A new

entity of drug-induced autoimmune encephalitis? Eur J Cancer 2017,in press.IF: 6,026

230.
S.K. Metzelder, T. Schroeder, M. Lübbert, M. Ditschkowski,.K.

Götze, S. Scholl, R.G. Meyer, P. Dreger, N. Basara, M.F. Fey, H.R.Salih, A. Finck, T. Pabst, A. Giagounidis, G. Kobbe,.E. Wollmer, J.Finke, A. Neubauer, A. Burchert: Long-term survival of sorafenib­treated FLT3-ITDepositive acute myeloid leukaemia patientsrelapsing after allogeneic stem cell transplantation. Eur J Cancer 2017, 86: 233-239. IF: 6,026

231.
Nagy Alexandra, Neubauer Andreas. Acute myeloid leukemia with myelodysplasia related changes. Atlas Genet Cytogenet OncolHaematol. 2017; 21(11):404-408.

232: Christine Feld, Peeyush Sahu, Miriam Frech, FlorianFinkernagel, Andrea Nist, Thorsten Stiewe, Uta Bauer* und Andreas Neubauer*: Combined cistrome and transcriptome analysis of SKI in AML cells identifies SKI as a co-repressor for RUNX1. Nucleic Acids Research 2018; doi: 10.1093/nar/gky119
* Geteilte Letztautorenschaft. IF: 10,162
233: Mathew NR, Baumgartner F, Braun L, O’Sullivan D, Thomas S,Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, IllertAL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, LübbertM, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M,Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R,Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C,Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S,Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U,Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre­de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R,Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, MüllerAM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D,van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M,Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornanD, Mufti G, Oran B, Rezvani K, Sha O, Negrin RS, Nagler A, PrinzM, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N,Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C,Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature medicine 2018; Feb 12. doi: 10.1038/nm.4484. [Epub ahead of print]
IF: 30,3
234.
Jerrentrup, A., Mueller, T., Glowalla, U., Herder, M.,Henrichs, N., Neubauer, A., Schaefer, J. R.:Teaching medicine with the help of „Dr. House“. PLoS One 2018; 13 (3) e0193972 IF: 3,54

235.
Miriam Frech, Sabine Teichler, Christine Feld, CarolineBouchard, Hannah Berberich, Katharina Sorg, Marco Mernberger, LarsBullinger, Uta-Maria Bauer, and Andreas Neubauer: MYB induces the expression of the oncogenic corepressor SKI in acute myeloidleukemia. Oncotarget 2018; 9(32):22423-22435.doi: 10.18632/oncotarget.25051IF: 5,168

236.
Frederick Fasslrinner, Johannes Schetelig, Andreas Burchert, Michael Kramer, Rudolf Trenschel, Ute Hegenbart, Michael Stadler,Kerstin Schäfer-Eckart, Michael Bätzel, Hans Eich, Martin Stuschke, Rita Engenhart-Cabillic, Mechthild Krause, Peter Dreger, Andreas Neubauer, Gerhard Ehninger, Dietrich Beelen, Wolfgang E Berdel, Timo Siepmann, Matthias Stelljes, Martin Bornhäuser: Long­term e cacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patientswith acute myeloid leukaemia in rst complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Hematology, 2018; 5: e161-e169. IF: 7,12

237.
Verena Nilius, Madeleine C. Killer, Nina Timmesfeld, Melina Schmitt, Roland Moll, Anja Lorch, Jörg Beyer, Elisabeth Mack,Michael Lohoff, Andreas Burchert, Andreas Neubauer & Cornelia Brendel: High ß-1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusion. Oncoimmunology 2018; 7, NO. 5, e1423169 (7 pages).IF: 7,719

238.
Stephanie Sasse, Helen Goergen, Annette Plu ¨tschow, BorisBöll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Josee ´M. Zijlstra, Richard Greil, Jana Markova, Max S. Topp,Julia Meissner, Andreas Neubauer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow: Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. J Clin Oncol 2018; DOI: 10.1200/JCO.2018.78.7192IF: 26,303

239.
Elisabeth K.M. Mack, Andre Marquardt, Danny Langer, PetraRoss, Alfred Ultsch, Michael G Kiehl, Hildegard I.D. Mack, TorstenHaferlach, Andreas Neubauer und Cornelia Brendel: Comprehensive

genetic diagnosis of acute myeloid leukemia by next-generation sequencing. Haematologica 2019; 104 (2) 277-287. IF: 9,090

240.
Sabrina Inselmann, Ying Wang, Susanne Saussele, Lea Fritz,Christin Schütz, Magdalena Huber, Simone Liebler, Thomas Ernst,Dali Cai, Sarah Botschek, Cornelia Brendel, Raffaele A. Calogero,Dinko Pavlinic, Vladimir Benes, Edison T. Liu, Andreas Neubauer,Andreas Hochhaus, and Andreas Burchert: Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in ChronicMyeloid Leukemia. Cancer Res 2018; 78: 6223-6234. IF: 9,130

241.
Christian Michel, Andreas Burchert, Andreas Hochhaus, SusanneSaussele, Andreas Neubauer, Michael Lauseker, Stefan W. Krause,Hans-Jochem Kolb, Dieter Kurt Hossfeld, Christoph Nerl, Gabriela

M. Baerlocher, Dominik Heim, Tim H Brümmendorf, Alice Fabarius,Claudia Haferlach, Brigitte Schlegelberger, Leopold Balleisen,Maria-Elisabeth Goebeler, Mathias Hänel, Anthony Ho, Jolanta Dengler, Christiane Falge, Robert Möhle, Stephan Kremers, MichaelKneba, Frank Stegelmann, Claus-Henning Köhne, Hans-Walter Lindemann, Cornelius F. Waller, Karsten Spiekermann, Wolfgang E.Berdel, Lothar Müller, Matthias Edinger, Jiri Mayer, Dietrich W. Beelen, Martin Bentz, Hartmut Link, Bernd Hertenstein, RolandFuchs, Martin Wernli, Frank Schlegel, Rudolf Schlag, Maike de Wit,Lorenz Trümper, Holger Hebart, Markus Hahn, Jörg Thomalla,Christof Scheid, Philippe Schafhausen, Walter Verbeek, Michael J. Eckart, Winfried Gassmann, Michael Schenk, Peter Brossart, ThomasWündisch, Thomas Geer, Stephan Bildat, Erhardt Schäfer, JoergHasford, Rüdiger Hehlmann, Markus Pfirrmann: Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica. 2018 Dec 4. pii: haematol.2018.206797. doi:10.3324/haematol.2018.206797.IF: 9,090
242.
Corinna Trenker, Christian Görg, Christian Jenssen, StefanKlein, Andreas Neubauer, Christoph F. Dietrich: The role of abdominal ultrasound in hematological diseases. Z Gastroenterol. 2018 Sep;56(9):1063-1076. doi: 10.1055/a-0603-4240. Epub 2018 Sep 17 IF: 1.612

243.
Saussele S, Hehlmann R, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Oppliger Leibundgut E, Heim D, Krause SW, Hofmann WK, Hasford J, PfirrmannM, Müller MC, Hochhaus A, Lauseker M: Defining therapy goals formajor molecular remission in chronic myeloid leukemia: results ofthe randomized CML Study IV. Leukemia. 2018 May;32(5):1222-1228. doi: 10.1038/s41375-018-0055-7. Epub 2018 Feb 26

IF: 10.023

244.
Schütz C, Inselmann S, Saussele S, Dietz CT, Müller MC,Eigendorff E, Brendel CA, Metzelder SK, Brümmendorf TH, Waller C,Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T,Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Mahon FX, Pfirrmann M, Burchert A: Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatmentdiscontinuation in CML. Leukemia. 2018 Apr;32(4):1054. doi:10.1038/leu.2017.348. Epub 2018 Jan 30. IF: 10.023

245.
Solovey M, Wang Y, Michel C, Metzeler KH, Herold T, GöthertJR, Ellenrieder V, Hessmann E, Gattenlöhner S, Neubauer A,Pavlinic D, Benes V, Rupp O, Burchert A.: „Nuclear factor of activated T-cells, NFATC1, governs FLT3ITD-driven hematopoieticstem cell transformation and a poor prognosis in AML“. J Hematol Oncol. 2019 Jul 8;12(1):72. doi: 10.1186/s13045-019-0765-y.IF: 8.731

246.
Laura Budau, Christian Wilhelm, Roland Moll, Jörg Jäkel, Carsten Hirt, Gottfried Dölken, Georg Maschmeyer, Ellen Neubauer, Konstantin Strauch, Andreas Burchert, Michael Herold, Andreas Neubauer: Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy inadvanced follicular lymphoma: a secondary analysis of a randomizedclinical trial. J Cancer Res Clin Oncol 2019; 145(8):2149-2156IF: 3,081

247.
A.E. Perl, G. Martinelli, J.E. Cortes, A. Neubauer, E.Berman, S. Paolini, P. Montesinos, M.R. Baer, R.A. Larson, C.Ustun, F. Fabbiano, H.P. Erba, A. Di Stasi, R. Stuart, R. Olin, M.Kasner, F. Ciceri, W.-C. Chou, N. Podoltsev, C. Recher, H. Yokoyama, N. Hosono, S.-S. Yoon, J.-H. Lee, T. Pardee, A.T. Fathi,

C. Liu, N. Hasabou, X. Liu, E. Bahceci, M.J. Levis: „Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML“. N Engl J Med 2019;381:1728-40. DOI: 10.1056/NEJMoa1902688″IF: 70.670
248.
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, DierlammJ, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A,de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R,Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J,Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S,Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance: Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with

aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9.IF: 35.386

249.
Michael Lübbert, Olga Grishina, Claudia Schmoor, Richard F. Schlenk, Edgar Jost, Martina Crysandt, Michael Heuser, FelicitasThol, Helmut R. Salih, Marcus M. Schittenhelm, Ulrich Germing,Andrea Kuendgen, Katharina S. Gotze, Hans-Walter Lindemann, Carsten Muller-Tidow, Gerhard Heil, Sebastian Scholl, Gesine Bug, Carsten Schwaenen, Aristoteles Giagounidis, Andreas Neubauer, Jurgen Krauter, Wolfram Brugger, Maike De Wit, Ralph Wasch, HeikoBecker, Annette M. May, Justus Duyster, Konstanze Dohner, Arnold Ganser, Bjorn Hackanson, Hartmut Dohner, on behalf of the DECIDERStudy Team: Valproate and Retinoic Acid in Combination WithDecitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia:Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. J Clin Oncol. 2019 Dec 3:JCO1901053. doi: 10.1200/JCO.19.01053IF: 28.349

250.
Michel C, Mack EKM, Mais CN, Fritz LV, Wang Y, Jehn LB, HühnSK, Simon C, Inselmann S, Marquardt A, Kremer J, Wollmer E, Sohlbach K, Neubauer A, Brendel CA, Haferlach C, Bange G, Burchert

A: Cloning and characterization of a novel druggable fusion kinasein acute myeloid leukemia. Haematologica. 2019 Dec 2. doi:10.3324/haematol.2019.237818.IF: 7.570
251.
Wilczynski A, Görg C, Timmesfeld N, Ramaswamy A, Neubauer A, Burchert A, Trenker C: Value and Diagnostic Accuracy ofUltrasound-Guided Full Core Needle Biopsy in the Diagnosis of Lymphadenopathy: A Retrospective Evaluation of 793 Cases. J Ultrasound Med. 2019 Oct 4. doi: 10.1002/jum.15134.IF: 1.718

252.
Stasik S, Middeke JM, Kramer M, Röllig C, Krämer A, Scholl S,Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B,Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause S, Herbst R, Hänel M, Frickhofen N,Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, PlatzbeckerU, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Bornhäuser M, Schetelig J, Thiede C: EZH2 mutations and impact on clinical outcome -an analysis in 1604 patients with newlydiagnosed acute myeloid leukemia. Haematologica. 2020 May;105(5):e228-e231. doi: 10.3324/haematol.2019.222323.IF: 7.570

253.
Nagler A, Labopin M, Dholaria B, Finke J, Brecht A, Schanz U, Niittyvuopio R, Neubauer A, Bornhäuser M, Santarone S, Beelen D, Shimoni A, Rösler W, Giebel S, Savani BN, Mohty M: Second allogeneic stem cell transplantation in patients with acute

lymphoblastic leukaemia: a study on behalf of the Acute LeukaemiaWorking Party of the European Society for Blood and MarrowTransplantation. Br J Haematol. 2019 Sep;186(5):767-776. doi: 10.1111/bjh.15973. Epub 2019 May 22IF: 5.206

254.
Gabriele Reinartz, Regina P. Pyra, Georg Lenz, RüdigerLiersch, Georg Stüben, Oliver Micke, Kay Willborn, Clemens F.Hess, Andreas Probst, Rainer Fietkau, Ralf Jany, Jürgen Schultze,Christian Rübe, Carsten Hirt, Wolfgang Fischbach, Martin Bentz,Severin Daum, Christiane Pott, Markus Tiemann, Peter Möller, Andreas Neubauer, Martin Wilhelm, Normann Willich, Wolfgang E. Berdel, Hans T. Eich: Favorable radiation field decrease in gastric marginal zone lymphoma. Strahlentherapie Onkologie 2019;in press.IF: 2,717

255.
Christen D, Sohlbach K, Metzelder SK, Wollmer E, Hoeffkes HG,Naumann R, Burchardt A, Rummel M, Trenker C, Dohse M, Mack E,Klameth A, Mann C, Kostrewa P, Brendel C, Wündisch T, Neubauer A,Wilhelm C, Burchert A.: Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogenic stem cell transplantation. Leukemia &Lymphoma 2019; epub ahead of print Jan 15.IF: 3,093

256.
Andreas Klameth, Andreas Neubauer, Christian Keller,Christian Aepinus, Ulrich Kaiser, Jörg Hoffmann, Cornelia Brendel: Aberrant CD3-Positive, CD8-Low, CD7-Negative Lymphocytes May Appear During Viral Infections and Mimic Peripheral T-Cell Lymphoma. Diagnostics 2020, 10, 204;doi:10.3390/diagnostics10040204.IF: 3.110

257.
Gabriele Reinartz, Caroline Molavi Tabrizi, Ruediger Liersch,Hanjöerg Ullerich, Dominik Hering, Kay Willborn, Juergen Schultze,Oliver Micke, Christian Ruebe, Wolfgang Fischbach, Martin Bentz,Severin Daum, Christiane Pott, Markus Tiemann, Peter Moeller,Andreas Neubauer, Martin Wilhelm, Georg Lenz, Wolfgang E. Berdel, Normann Willich, Hans E. Teich: Renaissance of Radiotherapy inIntestinal Lymphoma? 10-Year Efficacy and Tolerance in Multimodel Treatment of 134 Patients: Follow-up of Two German Multicenter Consecutive Prospective Phase II Trials. The Oncologist2020;25:e816-e832.IF: 5.025

258.
Donal P. McLornan, Vittoria Malpassuti, Anne Lippinkhof-Kozijn, Victoria Potter, Dietrich Beelen, Donald Bunjes, HenrikSengeloev, Aleksandar Radujkovic, Jakob Passweg, Yves Chalandon,Nicolaus Kröger, Gerald G. Wulf, Jan-Erik Johansson, Fabio Ciceri, Martin Bornhäuser, Ernst Holler, Blandine Guffroy, Sonja Martin,

Andreas Neubauer, Martin Gramatski, Marie Robin, Simona Iacobelli, Patrick Hayden, Juan C. Hernandez Boluda, Tomasz Czerw, IbrahimYakoub-Agha: Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: aretrospective study by the Chronic Malignancies Working Party ofEBMT. British Journal of Haematology 2020, doi: 10.1111/bjh.16537.IF: 5.020

259.
Christoph Röllig, Michael Kramer, Christoph Schliemann, Jan-Henrik Mikesch, Bjoern Steffen, Alwin Krämer, Richard Noppeney, Kerstin Schäfer-Eckart, Stefan W Krause, Mathias Haenel , Regina Herbst, Volker Kunzmann, Hermann Einsele, Edgar Jost, Tim HBrümmendorf, Sebastian Scholl, Andreas Hochhaus, Andreas Neubauer,Kristina Sohlbach, Lars Fransecky, Martin Kaufmann , Dirk Niemann,Markus Schaich, Norbert Frickhofen, Alexander Kiani, Frank Heits,Ulrich Krümpelmann, Ulrich Kaiser, Johannes Kullmer, Maxi Wass,Friedrich Stölzel, Malte von Bonin, Jan Moritz Middeke, Christian Thiede, Johannes Schetelig, Wolfgang E Berdel, Gerhard Ehninger, Claudia Baldus, Carsten Müller-Tidow, Uwe Platzbecker, Hubert Serve, Martin Bornhauser: Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acutemyeloid leukemia?. Blood 2020; 136: 823-830. IF: 16,601

260.
Lübbert M, Grishina O, Schmoor C, Schlenk RF, Jost E,Crysandt M, Heuser M, Thol F, Salih HR, Schittenhelm MM, GermingU, Kuendgen A, Götze KS, Lindemann HW, Müller-Tidow C, Heil G, Scholl S, Bug G, Schwaenen C, Giagounidis A, Neubauer A, Krauter J, Brugger W, De Wit M, Wäsch R, Becker H, May AM, Duyster J,Döhner K, Ganser A, Hackanson B, Döhner H: Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit PatientsWith Acute Myeloid Leukemia: Results of a Multicenter, Randomized,2 × 2, Phase II Trial. J Clin Oncol. 2020 Jan 20;38(3):257-270. doi: 10.1200/JCO.19.01053.IF: 32.958.

261.
Trenker C, Burchert A, Schumacher C, Schäfer JA, Dohse M,Timmesfeld N, Neubauer A, Sohlbach K, Michel C, Görg C.: Pathologic Hepatic Contrast-Enhanced Ultrasound Pattern in Patients Undergoing Allogeneic Stem Cell Transplantation. Ultrasound Med Biol. 2020 Aug;46(8):1865-1871. doi: 10.1016/j.ultrasmedbio.2020.03.001. Epub 2020 Jun 2.IF: 2.205.

262.
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C,Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, DierlammJ, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A,de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J,Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S,

Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M,Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance: Four versus six cycles of CHOP chemotherapy incombination with six applications of rituximab in patients withaggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2020 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9.IF: 60.392

263.
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L,Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B,Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb HJ,Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM,Burchert A, Brümmendorf TH, Hasford J, Hochhaus A, Saußele S,Baccarani M; SAKK and the German CML Study Group: High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020 May 7. doi: 10.1038/s41375-020-0826­

9. Online ahead of printIF: 12.104.
264.
Neubauer A, Wiesmann T, Vogelmeier CF, Mack E, Skevaki C, Gaik C, Keller C, Figiel J, Sohlbach K, Rolfes C, Renz H, Wulf H,Burchert A.: Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). Leukemia. 2020 Jun 17;1-3. doi: 10.1038/s41375-020-0907-9. Online ahead of print.IF: 12.104.

265.
H. Hackstein, A. Kalina, B. Dorn, I. S. Keil, N. Baal,

G. Michel, C. Brendel, A. Neubauer, T. Jakob and G. Bein: CD11c+dendritic cells mediate antigen-specific suppression in extracorporeal photopheresis. Clinical & Experimental Immunology 2020; in press.IF: 3.532
266.
Joerg Hoffmann, Marissa Rother, Ulrich Kaiser, Michael Thrun, Christian Wilhelm, Andrea Grün, Ute Niebergall, Ute Meissauer,Andreas Neubauer, Cornelia Brendel: Determination of CD43 and CD200 surface expression improves accuracy of B-cell lymphoma immunophenotyping. Cytometry B Clin Cytom 2020; 98: 476-482.10.1002/cyto.b.21936IF: 2.454

267.
Viviane Ponath, Miriam Frech, Mathis Bittermann, Reem AlKhayer, Andreas Neubauer, Cornelia Brendel and Elke Pogge von Strandmann: The Oncoprotein SKI Acts as A Suppressor of NK Cell-Mediated Immunosurveillance in PDAC. Cancers 2020; 12, 2857; doi:10.3390/cancers12102857IF: 6.639

268.
Jan-Niklas Eckardt, Sebastian Stasik, Michael Kramer,Christoph Röllig, Alwin Krämer, Sebastian Scholl, Andreas

Hochhaus, Martina Crysandt, Tim H. Brümmendorf, Ralph Naumann,Björn Steffen, Volker Kunzmann, Hermann Einsele, Markus Schaich,Andreas Burchert,Andreas Neubauer, Kerstin Schäfer-Eckart,Christoph Schliemann, Stefan W. Krause, Regina Herbst, MathiasHänel, Norbert Frickhofen, Richard Noppeney, Ulrich Kaiser, Claudia D. Baldus, Martin Kaufmann, Zdenek Rácil, Uwe Platzbecker, Wolfgang E. Berdel, Jirí Mayer, Hubert Serve, Carsten Müller-Tidow,Gerhard Ehninger, Friedrich Stölzel, Frank Kroschinsky, JohannesSchetelig, Martin Bornhäuser, Christian Thiede and Jan MoritzMiddeke: Loss-of-Function Mutations of BCOR Are an IndependentMarker of Adverse Outcomes in Intensively Treated Patients withAcute Myeloid Leukemia. Cancers 2021; 13: 2095. IF: 6.639

269.
Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C,Wollmer E, Wäsch R, Bornhäuser M, Berg T, Lang F, Ehninger G,Serve H, Zeiser R, Wagner EM, Kröger N, Wolschke C, Schleuning M,Götze KS, Schmid C, Crysandt M, Eßeling E, Wolf D, Wang Y, Böhm A,Thiede C, Haferlach T, Michel C, Bethge W, Wündisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes HG, Rospleszcz S, Burchardt A,Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder SK: Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol 2020; 38: 2992-3002. IF: 32,598

270.
Kriegsmann K, Hundemer M, Hofmeister-Mielke N, Reichert P, Manta CP, Awwad MHS, Sauer S, Bertsch U, Besemer B, Fenk R, HänelM, Munder M, Weisel KC, Blau IW, Neubauer A, Müller-Tidow C, Raab MS, Goldschmidt H, Huhn S, For The German-Speaking Myeloma Multicenter Group Gmmg: Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment. Cancers 2020; 12: 2322IF: 6,639

271.
Michel C, Mack EK, Mais CN, Fritz LV, Wang Y, Jehn LB, HühnSK, Simon C, Inselmann S, Marquardt A, Kremer J, Wollmer E,Sohlbach K, Neubauer A, Brendel CA, Haferlach C, Bange G, Burchert A.: Cloning and characterization of a novel druggable fusion kinase in acute myeloid leukemia. Haematologica 2020; 39: e395­e398. IF: 7,116

272.
Wilczynski A, Görg C, Timmesfeld N, Ramaswamy A, Neubauer A, Burchert A, Trenker C.: Value and Diagnostic Accuracy ofUltrasound-Guided Full Core Needle Biopsy in the Diagnosis of Lymphadenopathy: A Retrospective Evaluation of 793 Cases. J Ultrasound Med 2020; 39: 559-567. IF: 1,759

273.
Stasik S, Middeke JM, Kramer M, Röllig C, Krämer A, Scholl S,Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B,Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause S, Herbst R, Hänel M, Frickhofen N,Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, PlatzbeckerU, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Bornhäuser M, Schetelig J, Thiede C; Study Alliance Leukemia (SAL): EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia.Haematologica 2020; 105: e228-e231. IF: 7,116

274.
Middeke JM, Teipel R, Röllig C, Stasik S, Zebisch A, Sill H,Kramer M, Scholl S, Hochhaus A, Jost E, Brümmendorf TH, Naumann R, Steffen B, Serve H, Altmann H, Kunzmann V, Einsele H, ParmentierS, Schaich M, Burchert A, Neubauer A, Schliemann C, Berdel WE,Sockel K, Stölzel F, Platzbecker U, Ehninger G, Bornhäuser M,Schetelig J, Thiede C; Study Alliance Leukemia (SAL): Decitabine treatment in 311 patients with acute myeloid leukemia: outcome andimpact of TP53 mutations -a registry based analysis. Leuk Lymphoma 2021; 5:1-15. IF: 2,756

275.
Liss F, Frech M, Wang Y, Giel G, Fischer S, Simon C, WeberLM, Nist A, Stiewe T, Neubauer A, Burchert A, Liefke R: IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells. Cancers 2021; 13: 764.IF: 6,639

276.
Wertheimer T, Dohse M, Afram G, Weber D, Heidenreich M, Holler B, Kattner AS, Neubauer A, Mielke S, Ljungman P, Holler E, Herr W, Edinger M, Martínez AP, Fante M, Wolff D. Abatacept assalvage therapy in chronic graft-versus-host disease-a retrospective analysis. Ann Hematol 2021; 100: 779-787. IF: 2,838

277.
Röllig C, Serve H, Noppeney R, Hanoun M, Krug U, Baldus CD,Brandts CH, Kunzmann V, Einsele H, Krämer A, Müller-Tidow C, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Frickhofen N,Kullmer J, Kaiser U, Kiani A, Link H, Geer T, Reichle A, JunghanßC, Repp R, Meinhardt A, Dürk H, Klut IM, Bornhäuser M, Schaich M,Parmentier S, Görner M, Thiede C, von Bonin M, Platzbecker U, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study AllianceLeukaemia (SAL). Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia 2021; doi:10.1038/s41375-021-01148-x. Online ahead of print. PMID: 33603142 IF: 8,665

278.
Joerg Hoffmann, Andreas Klameth, Martin Russwurm, Andreas Neubauer, Cornelia Brendel: Peripheral T-cell lymphoma immunophenotype in a patient with a history of Muromonab-CD3 therapy: A case report and a diagnostic dilemma. Cytometry Part B:Clinical Cytometry, 2022; 102: 77-78. IF:

279.
Neubauer, A., Johow, J.,Mack, E., Burchert, A., Meyn, D., Kadlubiec, A., Torje, I., Wulf, H., Vogelmeier, C. F., Hoyer, J.,Skevaki, C., Muellenbach, R. M., Keller, C., Schade-Brittinger, C., Rolfes, C., Wiesmann, T.: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). Leukemia 2021, 35: 2917-2923. IF: 8,665

280.
Sebastian Stasik, Jan-Niklas Eckardt, Michael Kramer, Christoph Röllig, Alwin Krämer, Sebastian Scholl, AndreasHochhaus, Martina Crysandt, Tim H. Brümmendorf, Ralph Naumann,Björn Steffen, Volker Kunzmann, Hermann Einsele, Markus Schaich,Andreas Burchert, Andreas Neubauer, Kerstin Schäfer-Eckart, Christoph Schliemann, Stefan Krause, Regina Herbst, Mathias Hänel,Norbert Frickhofen, Richard Noppeney, Ulrich Kaiser, Claudia D.Baldus, Martin Kaufmann, Zdenek Rácil, Uwe Platzbecker, Wolfgang

E. Berdel, Jiri Mayer, Hubert Serve, Carsten Müller-Tidow, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig, Jan M. Middeke,Christian Thiede, on behalf of the Study Alliance Leukemia (SAL): Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. Blood Adv 2021; 5 (17):3279–3289. IF: 4,910
281. Leonie Gebauer, Andrea Nist, Marco Mernberger, ThorstenStiewe, Roland Moll, Kathleen Stabla, Uwe Klinge, Elisabeth Mack,Cornelia Brendel, and Andreas Neubauer: Superior Overall Survival in Patients with Colorectal Cancer, Regular Aspirin Use, andCombined Wild-Type PIK3CA and KRAS-Mutated Tumors. Cancers 2021;
13: 4959. (shared last authors) IF: 6,639
282.
Corinna Trenker, Jessica Kümpel, Christian Michel, EhsanSafai Zadeh, Christoph F. Dietrich, Nina Timmesfeld, Andreas Neubauer, Andreas Burchert, Christian Görg: Assessment of EarlyTherapy Response of Non-Hodgkin’s and Hodgkin’s Lymphoma Using B-Mode Ultrasound and Dynamic Contrast-Enhanced Ultrasound. Journal of Ultrasound in Medicine 2021; 9999:1–8IF: 2,153

283.
Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M,Barman L, Bennett K, Chakraborty S, Chang I, Cheung P, ChinthrajahS, Dhingra S, Do E, Finck A, Gaano A, Geßner R, Giannini HM, Gonzalez J, Greib S, Gündisch M, Hsu AR, Kuo A, Manohar M, Mao R,Neeli I, Neubauer A, Oniyide O, Powell AE, Puri R, Renz H, Schapiro J, Weidenbacher PA, Wittman R, Ahuja N, Chung HR,Jagannathan P, James JA, Kim PS, Meyer NJ, Nadeau KC, Radic M,Robinson WH, Singh U, Wang TT, Wherry EJ, Skevaki C, Luning PrakET, Utz PJ: New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021 Sep 14;12(1):5417. doi:10.1038/s41467-021-25509-3. IF: 17,7

284.
Franziska Taube, Julia Annabell Georgi, MichaelKramer,Sebastian Stasik, Jan Moritz Middeke,Christoph Röllig,UtzKrug, Alwin Krämer, Sebastian Scholl, Andreas Hochhaus, Tim H.Brümmendorf, Ralph Naumann, Andreas Petzold, Roger Mulet-Lazaro, Peter J. M. Valk, Björn Steffen, Hermann Einsele, Markus Schaich, Andreas Burchert, Andreas Neubauer, Kerstin Schäfer-Eckart, Christoph Schliemann, Stefan W. Krause, Mathias Hänel, Richard Noppeney, Ulrich Kaiser, Claudia D. Baldus, Martin Kaufmann, Sylvia Herold, Friedrich Stölzel, Katja Sockel, Malte von Bonin, Carsten Müller-Tidow, Uwe Platzbecker, Wolfgang E. Berdel, Hubert Serve, Gerhard Ehninger, Martin Bornhäuser,1, Johannes Schetelig,Christian Thiede, for the Study Alliance Leukemia (SAL): CEBPAmutations in 4708 patients with acute myeloid leukemia:differential impact of bZIP and TAD mutations on outcome. Blood2022; 139: 87-103. IF: 23,629

285: Perl, A. E., Larson, R. A., Podoltsev, N. A., Strickland, S. A., Wang, E. S., Atallah, E., Schiller, G. J., Martinelli, G.,Neubauer, A., Sierra, J., Montesinos, P., Récher, C., Yoon, S. S.,Hosono, N., Onozawa, M., Chiba, S., Kim, H. J., Hasabou, N., Lu,Q., Tiu, R., Levis, M. J.: Follow-up of patients with R/R FLT3­mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 2022; 139(23):3366-3375IF: 23,629
286. Elisabeth K. M. Mack, Sören Hartmann, Petra Ross, Ellen Wollmer, Christoph Mann, Andreas Neubauer, Cornelia Brendel, Jörg Hoffmann: Monitoring multiple myeloma in the peripheral bloodbased on cell-free DNA and circulating plasma cells. Ann Hematol2022; 2022;101(4):811-824. doi: 10.1007/s00277-022-04771-5.IF: 4,030
287: Sebastian Stasik, Michael Kramer, Sven Zukunft, ChristophRöllig, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Carsten Müller-Tidow, Kerstin Schäfer-Eckart, Martin Kaufmann, Stefan Krause, Tim Sauer, Mathias Hänel, Andreas Neubauer, Gerhard
Ehninger, Martin Bornhäuser, Johannes Schetelig, Jan M. Middeke and Christian Thiede on behalf of the Study Alliance Leukemia(SAL): Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD. Front Oncol 2022; 12: 862991 IF: 6,244
288: Riemer, Carolin, Mack, Elisabeth, Burchert, Andreas,Gündisch, Margrit, Greib, Sarah, Etati, Rojin, Tarawneh, Thomas,Karim, Ihab, Keller, Christian, Renz, Harald, Skevaki, Chrysanthi,Neubauer, Andreas, Michel, Christian: Dysgranulopoiesis in patients with coronavirus disease 2019. Acta Haematologica Polonica 2019; 52: 516-521.IF: 0,42
289: Miriam Rehberger, Jonas A. Schäfer, Anna-Maria Krampitz, Anne Catherine Bretz, Lukas Jost, Torsten Haferlach, Thorsten Stiewe,Andreas Neubauer: The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesisvia Mono-ubiquitination of PCNA. HemaSphere 2022; 6: e0708. IF: 9,1
290: Jörg Hoffmann, Samira Roesner & Andreas Neubauer: Rituximab induces a flare-up of activated neutrophil extracellular traps under in vitro conditions. Immunopharmacology and Immunotoxicology2022; https://doi.org/10.1080/08923973.2022.2088386IF: 3,236
291: Middeke, Jan M., Metzeler, Klaus H., Röllig, ChristophKrämer, Michael, Eckardt, Jan-Niklas, Stasik, Sebastian, Greif, Philipp A., Spiekermann, Karsten, Rothenberg-Thurley, Maja, Krug, Utz, Braess, Jan, Krämer, Alwin, Hochhaus, Andreas, Brümmendorf,Tim H., Naumann, Ralph, Steffen, Björn, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Görlich, Dennis, Sauerland, Cristina, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Frickhofen, Norbert,Noppeney, Richard, Kaiser, Ulrich, Kaufmann, Martin, Kunadt,Desiree, Wörmann, Bernhard, Sockel, Katja, von Bonin, Malte,Herold, Tobias, Müller-Tidow, Carsten, Platzbecker, Uwe, Berdel, Wolfgang E., Serve, Hubert, Baldus, Claudia D., Ehninger, Gerhard,Schetelig, Johannes, Hiddemann, Wolfgang, Bornhäuser, Martin,Stölzel, Friedrich, Thiede, Christian: Differential impact ofIDH1/2 mutational subclasses on outcome in adult AML: results froma large multicenter study. Blood Advances 2022; 6: 1394-1405. IF: 4,910
292:
Desiree Kunadt, Sebastian Stasik, Klaus H. Metzeler,Christoph Röllig, Christoph Schliemann, Philipp A. Greif, Karsten Spiekermann, Maja Rothenberg-Thurley, Utz Krug, Jan Braess, AlwinKrämer,Andreas Hochhaus, Sebastian Scholl, Inken Hilgendorf, Tim

H.
Brümmendorf, Edgar Jost, Björn Steffen,Gesine Bug, Hermann

Einsele, Dennis Görlich, Cristina Sauerland, Kerstin Schäfer-Eckart,Stefan W. Krause, Mathias Hänel, Maher Hanoun, MartinKaufmann, Bernhard Wörmann,Michael Kramer, Katja Sockel, KatharinaEgger-Heidrich, Tobias Herold, Gerhard Ehninger, Andreas Burchert,Uwe Platzbecker, Wolfgang E. Berdel, Carsten Müller-Tidow, WolfgangHiddemann, Hubert Serve, Matthias Stelljes, Claudia D. Baldus, Andreas Neubauer, Johannes Schetelig, Christian Thiede, Martin Bornhäuser, Jan M. Middeke, Friedrich Stölzel and the A. M. L.Cooperative Group (AMLCG), Study Alliance Leukemia (SAL): Impact of IDH1 and IDH2 mutational subgroups in AML patients afterallogeneic stem cell transplantation. Journal of Hematology & Oncology (2022) 15:126
IF: 23,17
293. Thomas S. Tarawneh, Fiona R. Rodepeter, Julia Teply-Szymanski, Petra Ross, Vera Koch, Clemens Thölken, Jonas A. Schäfer, Niklas Gremke, Hildegard I. D. Mack, Judith Gold, Jorge Riera-Knorrenschild, Christian Wilhelm, Anja Rinke, Martin Middeke, Andreas Klemmer, Marcel Romey, Akira Hattesohl, Moritz Jesinghaus, Christian Görg, Jens Figiel, Ho-Ryun Chung, Thomas Wündisch, Andreas Neubauer, Carsten Denkert, and Elisabeth K. M.Mack: Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis froman Institutional Molecular Tumor Board. Cancers 2022; 14: 4430.IF: 6,575
294: Devillier R, Galimard JE, Labopin M, Blaise D, Raiola AM,Pavlu J, Castagna L, Socié G, Chalandon Y, Martino M, Stölzel F,Bug G, Bruno B, Vrhovac R, Charbonnier A, Olivieri A, Bay JO,Arroyo H, Yakoub-Agha I, Avenoso D, Neubauer A, Nguyen S, Forcade E, Brissot E, Savani B, Nagler A, Mohty M (2022) Reduced intensityversus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT Bone Marrow Transplant 57:1421-1427 doi:10.1038/s41409-022-01674-xIF: 5,483
295.
Katharina Otte, Kai Zhao, Madita Braun, Andreas Neubauer, Hartmann Raifer, Frederik Helmprobst, Felipe Ovalle Barrera, Christopher Nimsky, Jörg W Bartsch, Tillmann Rusch: Eltanexor Effectively Reduces Viability of Glioblastoma andGlioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide. Biomedicines 2022; 10: 2145 IF: 4,757

296.
Eckardt, Jan-Niklas, Stasik, Sebastian, Röllig, Christoph, Sauer, Tim, Scholl, Sebastian, Hochhaus, Andreas, Crysandt,

Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert,Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann,Christoph, Krause, Stefan W., Herbst, Regina, Hänel, Mathias, Hanoun, Maher, Kaiser, Ulrich, Kaufmann, Martin, Rácil, ZdenekMayer, Jiri, Cerqueira, Tiago, Kroschinsky, Frank, Berdel,Wolfgang E., Serve, Hubert, Müller-Tidow, Carsten, Platzbecker, Uwe, Baldus, Claudia D., Schetelig, Johannes, Siepmann, Timo, Bornhäuser, Martin, Middeke, Jan Moritz, Thiede, Christian: Alterations of cohesin complex genes in acute myeloid leukemia:differential co-mutations, clinical presentation and impact on outcome. Blood Cancer J 2023; 13: 18p. IF: 9,812

297.
Hanoun M, Ruhnke L, Kramer M, Hanoun C, Schäfer-Eckart K, Steffen B, Sauer T, Krause SW, Schliemann C, Mikesch JH, KaufmannM, Hänel M, Jost E, Brümmendorf TH, Fransecky L, Kraus S, EinseleH, Niemann D, Neubauer A, Kullmer J, Seggewiss-Bernhard R, Görner M, Held G, Kaiser U, Scholl S, Hochhaus A, Reinhardt HC,Platzbecker U, Baldus CD, Müller-Tidow C, Bornhäuser M, Serve H, Röllig C (2022) Intensified cytarabine dose during consolidationin adult AML patients under 65 years is not associated withsurvival benefit: real-world data from the German SAL-AML registry J Cancer Res Clin Oncol doi:10.1007/s00432-022-04356-9IF: 4,322

298.
Feng A, Yang EY, Moore AR, Dhingra S, Chang SE, Yin X, Pi R,Mack EKM, Völkel S, Geßner R, Gündisch M, Neubauer A, Renz H,Tsiodras S, Fragkou PC, Asuni AA, Levitt JE, Wilson JG, Leong M,Lumb JH, Mao R, Pinedo K, Roque J, Richards CM, Stabile M,Swaminathan G, Salagianni ML, Triantafyllia V, Bertrams W, BlishCA, Carette JE, Frankovich J, Meffre E, Nadeau KC, Singh U, Wang TT, Luning Prak ET, Herold S, Andreakos E, Schmeck B, Skevaki C,Rogers AJ, Utz PJ (2023) Autoantibodies are highly prevalent innon–SARS-CoV-2 respiratory infections and critical illness JCI Insight 8 doi:10.1172/jci.insight.163150IF: 9,484

299.
Thrun, M. C., Mack, E. K. M., Neubauer, A., Haferlach, T.,Frech, M., Ultsch, A., & Brendel, C. (2022). A Bioinformatics View on Acute Myeloid Leukemia Surface Molecules by Combined Bayesianand ABC Analysis. Bioengineering, 9(11), 642.IF: 5,046

300.
Rummelt C, Grishina O, Schmoor C, Crysandt M, Heuser M, GötzeKS, Schlenk RF, Döhner K, Salih HR, Heil G, Müller-Tidow C, Brugger W, Kündgen A, De Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, Al-Ali HK, Wäsch R, Becker H, May AM, Duyster J, Hackanson B, Ganser A, Döhner H, Lübbert M (2023) Activity ofdecitabine combined with all-trans retinoic acid in oligoblastic

AML: Results from a randomized 2×2 phase II trial (DECIDER).Haematologica doi:10.3324/haematol.2022.282258IF: 11,04

301.
Hoffmann J, Etati R, Brendel C, Neubauer A, Mack E (2022):The Low Expression of Fc-Gamma Receptor III (CD16) and High Expression of Fc-Gamma Receptor I (CD64) on Neutrophil Granulocytes Mark Severe COVID-19 Pneumonia. Diagnostics (Basel)12 doi:10.3390/diagnostics12082010IF: 3,7

302.
Spyridonidis A, Labopin M, Savani B, Giebel S, Bug G,Schönland S, Kröger N, Stelljes M, Schroeder T, McDonald A, BlauIW, Bornhäuser M, Rovira M, Bethge W, Neubauer A, Ganser A,Bourhis JH, Edinger M, Lioure B, Wulf G, Schäfer-Eckart K, Arat M, Peric Z, Schmid C, Bazarbachi A, Ciceri F, Nagler A, Mohty M(2023) Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute LeukemiaWorking Party of the EBMT. Hemasphere 7:e812doi:10.1097/hs9.0000000000000812IF: 9,1

303.
Ruhnke L, Röllig C, Herold S, Sauer T, Brandts CH, Steffen B,Schäfer-Eckart K, Krause SW, Hänel M, Reichle A, Scholl S, Neubauer A, Mikesch JH, Schetelig J, Stölzel F, Kramer M, Haake A,Frimmel J, Krämer A, Schlenk R, Platzbecker U, Serve H, Baldus CD,Müller-Tidow C, Aust D, Bornhäuser M, Ehninger G, Thiede C (2023) Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial. Haematologicadoi:10.3324/haematol.2022.281636IF: 11,04

304.
Hoffmann J, Eminovic S, Wilhelm C, Krause SW, Neubauer A,Thrun MC, Ultsch A, Brendel C (2023) Prediction of ClinicalOutcomes with Explainable Artificial Intelligence in Patients withChronic Lymphocytic Leukemia. Curr Oncol 30:1903-1915 doi:10.3390/curroncol30020148IF: 3,109

305.
Greve G, Andrieux G, Schlosser P, Blagitko-Dorfs N, Rehman UU, Ma T, Pfeifer D, Heil G, Neubauer A, Krauter J, Heuser M, Salih HR, Döhner K, Döhner H, Hackanson B, Boerries M, Lübbert M(2023) In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts. Leukemia doi:10.1038/s41375-023-01876-2 IF: 12,256

306.
Abou Dalle I, Labopin M, Kröger N, Schroeder T, Finke J,Stelljes M, Neubauer A, Blaise D, Yakoub-Agha I, Salmenniemi U,

Forcade E, Itäla-Remes M, Dreger P, Bug G, Passweg J, Heuser M, Choi G, Brissot E, Giebel S, Nagler A, Ciceri F, Bazarbachi A,Mohty M (2023) Impact of disease burden on clinical outcomes ofAML patients receiving allogeneic hematopoietic celltransplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant doi:10.1038/s41409-023-01961-1IF: 5,431

307.
Heidenreich F, Falk B, Baldauf H, Massalski C, Schäfer G,Rücker-Braun E, Altmann H, Sauter J, Solloch U, Lange V, Stölzel F, Röllig C, Middeke JM, von Bonin M, Thiede C, Schäfer-Eckart K, Müller-Tidow C, Krause SW, Kraus S, Kaufmann M, Hänel M, Serve H, Neubauer A, Bornhäuser M, Schmidt AH, Schetelig J (2023) Largecase-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia. Blood Adv doi:10.1182/bloodadvances.2022008514IF: 7,637

308.
Hoffmann J, Thrun MC, Röhnert MA, von Bonin M, Oelschlägel U,Neubauer A, Ultsch A, Brendel C (2023) Identification of critical hemodilution by artificial intelligence in bone marrow assessedfor minimal residual disease analysis in acute myeloid leukemia:The Cinderella method. Cytometry A 103:304-312 doi:10.1002/cyto.a.24686IF: 4,714

309.
Maurer E, Eilsberger F, Wächter S, Riera Knorrenschild J,Pehl A, Holzer K, Neubauer A, Luster M, Bartsch DK (2023)Mutation-based, short-term “neoadjuvant” treatment allows resectability in stage IVB and C anaplastic thyroid cancer.European Archives of Oto-Rhino-Laryngology 280:1509-1518 doi:10.1007/s00405-023-07827-yIF: 3,236

310.
Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES,Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J,Montesinos P, Recher C, Yoon S-S, Maeda Y, Hosono N, Onozawa M, Kato T, Kim H-J, Hasabou N, Nuthethi R, Tiu R, Levis MJ (2023) Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.Transplantation and Cellular Therapy 29:265.e261-265.e210 doi:https://doi.org/10.1016/j.jtct.2022.12.006IF: 5,609

311.
Holstege A, Krause S, Neubauer A, Werdan K, Schellong S (2023) Klug entscheiden in der Inneren Medizin: Sechs neueEmpfehlungen Deutsches Ärzteblatt 120:A768-A772IF: 1,811

312.
Hoffmann J, Schliesser G, Neubauer A (2023) Abatacept assalvage therapy for life-threatening refractory autoimmune hemolytic anemia: a case report. Hematology 28:2208010doi:10.1080/16078454.2023.2208010IF: 2,269

313.
Völkel S, Tarawneh TS, Sacher L, Bhagwat AM, Karim I, MackHID, Wiesmann T, Beutel B, Hoyer J, Keller C, Renz H, Burchert A,Neubauer A, Graumann J, Skevaki C, Mack EKM (2023) Serumproteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib. Front Med (Lausanne) 10:1176427doi:10.3389/fmed.2023.1176427IF: 5,058

314.
Georgi JA, Stasik S, Eckardt JN, Zukunft S, Hartwig M, RolligC, Middeke JM, Oelschlagel U, Krug U, Sauer T, Scholl S, HochhausA, Brummendorf TH, Naumann R, Steffen B, Einsele H, Schaich M,Burchert A, Neubauer A, Schafer-Eckart K, Schliemann C, Krause SW, Hanel M, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Muller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornhauser M,Schetelig J, Kroschinsky F, Thiede C, Study Alliance L (2023) UBTFtandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferioroutcome Blood cancer journal 13:88 doi:10.1038/s41408-023-00858-yIF: 11,68

315.
Das Gupta D, Paul C, Samel N, Bieringer M, Staudenraus D,Marini F, Raifer H, Menke L, Hansal L, Camara B, Roth E, Daum P,Wanzel M, Mernberger M, Nist A, Bauer U-M, Helmprobst F, Buchholz M, Roth K, Bastian L, Hartmann AM, Baldus C, Ikuta K, Neubauer A,Burchert A, Jäck H-M, Klein M, Bopp T, Stiewe T, Pagenstecher A, Lohoff M (2022) IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferringIL-7 hypersensitivity Cell Death & Differentiation 29:2163-2176 doi:10.1038/s41418-022-01005-zIF: 12,4

316.
Eckardt J-N, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, Scholl S, Hochhaus A, Crysandt M, BrümmendorfTH, Krug U, Wörmann B, Hiddemann W, Görlich D, Sauerland C,Steffen B, Einsele H, Neubauer A, Burchert A, Schäfer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hänel M, Hanoun M, Kaufmann M,Fransecky L, Braess J, Ruhnke L, Schetelig J, Middeke JM, Serve H,Baldus CD, Platzbecker U, Müller-Tidow C, Bornhäuser M, Herold T, Thiede C, Röllig C (2023) Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications forthe European leukemia net risk classification Leukemiadoi:10.1038/s41375-023-02016-6IF: 12,256

317.
Eckardt J-N, Stasik S, Röllig C, Petzold A, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B,Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Hanoun M,Kaiser U, Kaufmann M, Rácil Z, Mayer J, Oelschlägel U, Berdel WE,Ehninger G, Serve H, Müller-Tidow C, Platzbecker U, Baldus CD, Dahl A, Schetelig J, Bornhäuser M, Middeke JM, Thiede C (2023) Mutated IKZF1 is an independent marker of adverse risk in acutemyeloid leukemia Leukemia doi:10.1038/s41375-023-02061-1IF: 12,256

318.
Bauer C, Mack E, Hefter V, Fischer A, Volland K, Skevaki C,Neubauer A, Gress T, Becker S, Keller C (2023) Impaired systemic nucleocapsid antigen clearance in severe COVID-19 J Med Virol 95:e29032 doi:10.1002/jmv.29032IF: 12,7

319.
Alkhayer R, Ponath V, Frech M, Adhikary T, Graumann J,Neubauer A, von Strandmann EP (2023) KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a noveltherapeutic target identified by enChIP. Cell Commun Signal 21:94doi:10.1186/s12964-023-01118-zIF: 8,4

320.
Kröger N, Wulf G, Hegenbart U, Burchert A, Stelljes M,Gagelmann N, Brecht A, Kaufmann M, Müller L, Ganser A, Wolf D,Bethge W, Bornhäuser M, Kiehl M, Wagner EM, Schmid C, ReinhardtHC, Kobbe G, Salwender H, Heinicke T, Kropff M, Heinzelmann M,Ayuk F, Trümper L, Neubauer A, Völp A, Kluychnikov E, Schönland S,Wolschke C (2024) Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomidefor multiple myeloma patients less than 60 years of age: aprospective phase II study. Haematologica 109:1469-1479 doi:10.3324/haematol.2023.282920IF: 10,1

321.
Wiemers H, Burchert A, Michel C, Sohlbach K, Schäfer J,Neubauer A, Görg C, Trenker C (2024) Prospective Assessment ofTreatment-Induced Liver Injury as a Cause of Diffuse Pathologic Hepatic Enhancement in Contrast-Enhanced Ultrasound Ultrasound Med Biol 50:224-228 doi:10.1016/j.ultrasmedbio.2023.10.003IF: 2,9

322.
Hoffmann J, Rheude A, Neubauer A, Brendel C, Thrun MC (2024) Development of an explainable AI system using routine clinicalparameters for rapid differentiation of inflammatory conditionsFront Immunol 15:1364954 doi:10.3389/fimmu.2024.1364954IF: 9,4

323.
Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S,Pohlmann A, Schliemann C, Mikesch JH, Steffen B, Sauer T, Hanoun

M, Schafer-Eckart K, Krause SW, Hanel M, Einsele H, Jost E, Brummendorf TH, Scholl S, Hochhaus A, Neubauer A, Burchert A,Kaufmann M, Niemann D, Schaich M, Blau W, Kiani A, Gorner M,Kaiser U, Kullmer J, Weber T, Berdel WE, Ehninger G, Muller-Tidow C, Platzbecker U, Serve H, Bornhauser M, Rollig C, Baldus CD,Fransecky L (2024) Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated withvenetoclax-based regimens Haematologica 109:2469-2477 doi:10.3324/haematol.2024.285225IF: 8,2

324.
Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N,Herbst R, Hänel M, Noppeney R, Hanoun M, Kaufmann M, WeinbergerovaB, Schäfer-Eckart K, Sauer T, Neubauer A, Burchert A, Baldus CD,Mertová J, Jost E, Niemann D, Novák J, Krause SW, Scholl S,Hochhaus A, Held G, Szotkowski T, Rank A, Schmid C, Fransecky L,Kayser S, Schaich M, Kramer M, Fiebig F, Haake A, Schetelig J,Middeke JM, Stölzel F, Platzbecker U, Thiede C, Müller-Tidow C, Berdel WE, Ehninger G, Mayer J, Serve H, Bornhäuser M (2024)Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The RandomizedDaunoDouble Trial by the Study Alliance Leukemia J ClinOncol:Jco2400235 doi:10.1200/jco.24.00235IF: 42,1

325.
Fischer S, Weber LM, Stielow B, Frech M, Simon C, Geller M,Könnecke J, Finkernagel F, Forné I, Nist A, Bauer UM, Stiewe T,Neubauer A, Liefke R (2024) IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acutemyeloid leukemia (AML) cells Nucleic Acids Res 52:7590-7609 doi:10.1093/nar/gkae437IF: 19,16

326.
Gremke N, Rodepeter FR, Teply-Szymanski J, Griewing S, Boekhoff J, Stroh A, Tarawneh TS, Riera-Knorrenschild J, Balser C, Hattesohl A, Middeke M, Ross P, Litmeyer AS, Romey M, Stiewe T,Wündisch T, Neubauer A, Denkert C, Wagner U, Mack EKM (2024) NGS-Guided Precision Oncology in Breast Cancer and GynecologicalTumors-A Retrospective Molecular Tumor Board Analysis Cancers 16 doi:10.3390/cancers16081561IF: 6,575

327.
Tarawneh TS, Mack EKM, Faoro C, Neubauer A, Middeke M,Kirschbaum A, Holland A (2024) Diagnostic and therapeutic delaysin lung cancer during the COVID-19 pandemic: a single center experience at a German Cancer center. BMC Pulmonary Medicine24:320 doi:10.1186/s12890-024-03082-xIF: 3,1

328.
Jesús Duque-Afonso1, Jürgen Finke1, Maud Ngoya2, Jacques-Emmanuel Galimard2, Johannes Schetelig3, Matthias Eder4, Wolf

Rösler5, Gesine Bug6, Andreas Neubauer7, Matthias Edinger8, Gerald.
G. Wulf9, Pavel Jindra10, Hermann Einsele11, Matthias Stelljes12,Dominik Selleslag13, Eva Maria Wagner-Drouet14, Donald Bunjes15,Alexandros Spyridonidis16, Eolia Brissot17, Arnon Nagler18, FabioCiceri19, Mohamad Mohty17: Comparison of Fludarabine/Melphalan(FM140) with Fludarabine/Melphalan/BCNU (FBM110) in patients withrelapsed/refractory AML undergoing allogeneic hematopoietic celltransplantation – a Registry study on behalf of the EBMT AcuteLeukemia Working Party. BMT, in press 2024IF: 4,5
329.
Lübbert M, Wijermans PW, Kicinski M, Chantepie S, Van derVelden W, Noppeney R, Griškevicius L, Neubauer A, Crysandt M,Vrhovac R, Luppi M, Fuhrmann S, Audisio E, Candoni A, Legrand O,Foà R, Gaidano G, van Lammeren-Venema D, Posthuma EFM, Hoogendoorn M, Giraut A, Stevens-Kroef M, Jansen JH, de Graaf AO, Efficace F, Ammatuna E, Vilque JP, Wäsch R, Becker H, Blijlevens N, Dührsen U, Baron F, Suciu S, Amadori S, Venditti A, Huls G (2023) 10-day decitabine versus 3+7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial Lancet Haematol 10:e879-e889 doi:10.1016/s2352-3026(23)00273-9IF: 14,5

330.
Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S,Hanoun M, Schroeder T, Fransecky L, Steffen B, Krause SW, SchollS, Hochhaus A, Sauer T, Kraus S, Schäfer-Eckart K, Kaufmann M, Jost E, Brümmendorf TH, Schliemann C, Mikesch JH, Krug U, Hänel M,Morgner A, Schaich M, Neubauer A, Repp R, Niemann D, Seggewiss-Bernhardt R, Meinhardt A, Kullmer J, Kaiser U, Blau W, Kiani A,Grigoleit GU, Giagounidis A, Wurm AA, Altmann H, Middeke JMM,Schetelig J, Müller-Tidow C, Stölzel F, Baldus CD, Platzbecker U, Serve H, Bornhäuser M, Thiede C, Röllig C (2024) Validation of theRevised 2022 European LeukemiaNet Risk Stratification in AdultPatients with Acute Myeloid Leukemia. Blood Adv doi:10.1182/bloodadvances.2024013304IF: 7,4

331.
Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, RehmanUU, Crysandt M, Jost E, Thol F, Heuser M, Götze KS, Schlenk RF,Salih HR, Schittenhelm MM, Heil G, Schwaenen C, Müller-Tidow C, Brugger W, Kündgen A, de Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, May AM, Wäsch R, Duyster J, Döhner K, GanserA, Döhner H, Hackanson B, Becker H, Lübbert M (2024) Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine. Eur J Haematol doi:10.1111/ejh.14304IF: 2,3

332.
Acker F, Chromik J, Tiedjen E, Wolf S, Vischedyk JB, MakowkaP, Enßle JC, Kouidri K, Sebastian M, Steffen B, Oellerich T, Serve

H, Neubauer A, Schäfer JA, Bittenbring JT (2024) Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit forintensive therapy Eur J Haematol 113:623-630 doi:10.1111/ejh.14278IF: 2,3

333.
Devillier R, Galimard JE, Blaise D, Raiola AM, Bramanti S,Grillo G, Pastano R, de Latour RP, Busca A, López-Corral L, Rodríguez AB, Schmid C, Forcade E, Vydra J, Solano C, Bug G,Neubauer A, Charbonnier A, Brissot E, Nagler A, Ciceri F, Mohty M(2024) Peripheral blood stem cell versus bone marrow graft forpatients =60years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia incomplete remission: An analysis of the Acute Leukemia WorkingParty of the European Society for Blood and Marrow Transplantation Am J Hematol 99:1250-1256 doi:10.1002/ajh.27343IF: 12,8

334.
Efficace F, Kicinski M, Coens C, Suciu S, van der Velden W, Noppeney R, Chantepie S, Griskevicius L, Neubauer A, Audisio E,Luppi M, Fuhrmann S, Foà R, Crysandt M, Gaidano G, Vrhovac R,Venditti A, Posthuma EFM, Candoni A, Baron F, Legrand O,Mengarelli A, Fazi P, Vignetti M, Giraut A, Wijermans PW, Huls G,Lübbert M (2024) Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial Blood 144:541-551 doi:10.1182/blood.2023023625IF: 21

335.
Schmälter AK, Labopin M, Versluis J, Gallego Hernanz MP, EderM, von dem Borne P, Socié G, Chevallier P, Forcade E, Neubauer A,Baron F, Bazarbachi A, Bug G, Nagler A, Schmid C, Esteve J, MohtyM, Ciceri F (2025) The role of allogeneic stem celltransplantation in acute myeloid leukemia with translocationt(8;16)(p11;p13) Am J Hematol 100:85-92 doi:10.1002/ajh.27496IF: 13,265

336.
Zhao K, Braun M, Meyer L, Otte K, Raifer H, Helmprobst F,Möschl V, Pagenstecher A, Urban H, Ronellenfitsch MW, SteinbachJP, Pesek J, Watzer B, Nockher WA, Taudte RV, Neubauer A, NimskyC, Bartsch JW, Rusch T (2024) A Novel Approach for GlioblastomaTreatment by Combining Apoptosis Inducers (TMZ, MTX, andCytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477)Inhibiting XPO1, Bcl-2, and Mcl-1. Cells 13:632 IF: 5,1

337.
Duque-Afonso J, Finke J, Ngoya M, Galimard JE, Schetelig J, Eder M, Rösler W, Bug G, Neubauer A, Edinger M, Wulf GG, Jindra P,Einsele H, Stelljes M, Selleslag D, Wagner-Drouet EM, Bunjes D, Spyridonidis A, Brissot E, Nagler A, Ciceri F, Mohty M (2024) Comparison of fludarabine/melphalan (FM140) withfludarabine/melphalan/BCNU (FBM110) in patients with

relapsed/refractory AML undergoing allogeneic hematopoietic celltransplantation -a registry study on behalf of the EBMT AcuteLeukemia Working Party. Bone Marrow Transplant doi:10.1038/s41409­024-02499-6 IF: 4,5

338.
Stasik S, Eckardt J-N, Röllig C, Baldus CD, Platzbecker U, Serve H, Müller-Tidow C, Schäfer-Eckart K, Kaufmann M, Krause SW, Sauer T, Hänel M, Neubauer A, Ehninger G, Bornhäuser M, ScheteligJ, Middeke JM, Thiede C, Leukemia tSA The N159S mutation isassociated with poor outcome and a distinct molecular profile inadult patients with AML. British Journal of Haematology n/adoi:https://doi.org/10.1111/bjh.20027IF: 5,7

339.
Esteve J, Nagler A, Labopin M, Versluis J, Sanz J, Gedde-Dahl T, Burns D, Roeven M, Labussière-Wallet H, Borne PVD, Van Gorkom G, Contentin N, Neubauer A, Wagner-Drouet EM, Kröger N, Mohty M, Ciceri F (2025) Allogeneic Hematopoietic Cell Transplantation inPatients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. ARetrospective Analysis on Behalf of the Acute Leukemia WorkingParty of the EBMT. American Journal of Hematology 100:954-962 doi:https://doi.org/10.1002/ajh.27647IF: 10,1

340.
Mack E, Rau C, Otet C, Schäfer JA, Brendel C, Grass A, BredowP, Hohl C, Denkert C, Willeke F, Neubauer A (2025) High-dose vitamin C as a targeted treatment for KRAS-driven cancers? Redox Biology 85:103726 doi:https://doi.org/10.1016/j.redox.2025.103726IF: 10,7

Übersichten
1.
Neubauer A, Herrmann R: Interferon in der Therapie niedrigmaligner Non Hodgkin Lymphome. Med Klinik 84:355-359, 1989. IF: 0.4

2.
Neubauer A: Bedeutung molekulargenetischer Befunde für Diagnoseund Beurteilung der Prognose bei lymphatischen undhämatopoetischen Systemerkrankungen. LabMed. 18: 361-362, 1994. IF: 0.3

3.
Neubauer A, Richiero K, Huhn D: Alterations of the retinoblastoma susceptibility gene in chronic lymphocyticleukemia. Leuk Lymph, 18: 399-404, 1995.IF: 1.1

4.
Neubauer A, Thiede C, Huhn D, Wittig B: P53 and induction ofapoptosis as target for anticancer therapy. Leukemia, 10 / Suppl3, S2-S4, 1996.

IF: 3.5

5.
Morgner A, Bayerdörffer E, Neubauer A, Stolte M: Gastric MALTlymphoma and its relationsship to Helicobacter pylori infection: Management and pathogenesis of disease. Microscopy Research andTechnique 48: 349-56, 2000IF: 1.1

6.
Brendel C, Neubauer A: Characteristics and analysis of normaland leukemic stem cells: current concepts and future directions.Leukemia 14: 1711-1717, 2000. IF: 3.5

7.
Zugmaier G, Aigner A, Knabbe C, Neubauer A, Jaeger R:Differential secretion of heparin-binding growth factors by small cell-and non-small-cell lung cancer cell lines. Research Advances in Cancer 1: 11-13, 2001.IF: ­

8.
Wündisch T, Thiede C, Alpen B, Stolte M, Neubauer A: Are lymphocytic monoclonality and immunoglobulin heavy chain (IgH)rearrangement premalignant conditions in chronic gastritis?Microscopy Research and Technique 53: 414-418, 2001.IF: 1.1

9.
Neubauer A: Gene arrays in the diagnosis of non-Hodgkin´s lymphoma and leukaemia. EHA Educational book, Hematology Journal,2-5, 2001.IF: ­

10.
Hofbauer L, Neubauer A, Heufelder A: Receptor Activator ofNuclear Factor-kB Ligand and Osteoprotegerin: PotentialImplications for the Pathogenesis and Treatment of Malignant BoneDiseases. Cancer 92: 460-470, 2001.IF: 3.5

11.
Alpen B, Thiede C, Wündisch T, Bayerdörffer E, Stolte M,Neubauer A: Molecular diagnostics in low-grade gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type after Helicobacter pylori eradication therapy. Clinical Lymphoma2: 103-108, 2001.IF: 1999 noch nicht gelistet

12.
Morgner A, Thiede C, Bayerdörffer E, Alpen B, Wündisch T,Neubauer A, Stolte M: Long term follow up of gastric MALT lymphomaafter H.pylori eradication. Current Gastroenterology Reports 3: 516-522, 2001.IF: ­

13.
Morgner A, Bayerdörffer E, Neubauer A, Stolte M: Helicobacterpylori associated gastric B cell MALT lymphoma: predictive factorsfor regression (Commentary). Gut 48: 290-292, 2001. IF: 5.7

14.
Morgner A, Bayerdörffer E, Thiede C, Alpen B, Wündisch Th,Neubauer A, Stolte M: Bedeutung der Helicobacter pylori Infektionfür die Pathogenese und Therapie von MALT Lymphomen des Magens.Chir. Gastroenterol 18: 24-28, 2002.IF: 0.1

15.
Neubauer A: Konsequenzen des deutschen Antikorruptionsgesetzesfür die Drittmittelförderung an Universitätskliniken. Wiener MedWschr 152: 246-248, 2002.IF: ­

16.
Burchert A., Neubauer A: Molekulargenetische Diagnostik in derHämatologie und Onkologie Internist 46, 81-89, 2002. IF: 0.2

17.
Stolte M, Bayerdörffer E, Morgner A, Alpen B, Wündisch T,Thiede C, Neubauer A: Helicobacter and gastric MALT lymphoma. Gut,50, suppl 3, iii19-24, 2002.IF: 5.7

18.
Neubauer A, Wolf M, Engenhart Cabilic R, Rothmund M: Funktionund Aufgabe eines interdisziplinären Tumorzentrums: Notwendigkeiteines „Cancer Center“ für multimodale Therapiekonzepte. Dtsch Med Wschr 127: 901-906, 2002.IF: 0.6

19.
Wündisch T, Kim TD, Thiede C, Morgner A, Alpen B, Stolte M,Neubauer A: Etiology and therapy of Helicobacter pylori-associated gastric lymphomas. Ann Hematol 2003, 82: 535-545.IF: 1.8

20.
Heuser M, Wingen LU, Ritter M, Neubauer A. Schlegelberger B:Die Plattform „Signaltransduktion, Genomics/Proteomics“. Med Welt 55: 307-311, 2004.

21.
Burchert A, Neubauer A: Interferon alpha and T-cell responses in chronic myeloid leukemia. Leuk Lymphoma 46: 167-175, 2005.IF: 1.1

22.
Wollmer E, Neubauer A: General and special anaemia diagnostics. Der Internist 48: 1269-78, 2006 .IF: 0,36

23.
Morgner A, Fischbach W, Neubauer A: Therapieoptionen undPrognose gastrointestinaler Lymphome. Verdauungskrankheiten 25: 257-65, 2007.

24.
Wilhelm C, Neubauer A: Molekulare Tumortherapie. Der Internist49: 581-592, 2008.

25.
Neubauer, A., Mössner, J.: Antikörpertherapie (Editorial) Internist, 49: 917-918; 2008

26.
Schäfer J, Jerrentrup A. Neubauer A: New approaches to lecturemedicine -or: what can we learn from television? Dtsch Med Wschr 135: 2596-2600, 2010.

27.
Burchert A, Neubauer A: Chronische myeloische Leukämie. DerInternist, 52: 283-295, 2011.

28.
Neubauer A., Schlag P.: Vom Molekül zur Therapie. Der Onkologe17: 474-476, 2011.

29.
Wollmer E, Neubauer A: Nebenwirkungen der medikamentösenTumortherapie. Der Internist 2011; 52: 1429-1446.

30.
Wollmer E, Neubauer A: Komplikationen der allogenenKnochenmark-und Stammzelltransplantation. Der Internist 2014;55:547–561

31.
Michel C, Neubauer A, Burchert A: Molekulare Tumortherapie.Der Internist 2015; 56:1389–1402

32.
Michel C, Neubauer A, Burchert A: Kinasen als Zielemolekularer Tumortherapie. Onkologe 2016; 22: 40-49.

33.
Nagy A, Neubauer A: Acute myeloid leukemia with myelodysplasiarelated changes. Atlas Genet Cytogenet Oncol Haematol. in press,2017

On line version: http://AtlasGeneticsOncology.org/Anomalies/AMLwithmyelodysplID2041.html

34.
Neubauer Andreas: Immuntherapie von Tumorerkrankungen mitCheckpoint-Inhibitoren: Nicht nur beim malignen Melanom. Der Internist 2017; 58(4):409-423 IF: 0,36

35.
Krause S, Neubauer A: Klug entscheiden in der Hämatologie undOnkologie. Internist 2017; 58: 545-549.IF: 0,36

36.
Stefan W. Krause, Michael Oldenburg, Michael Hallek, Andreas Neubauer: Prioritäten deutscher Onkologen. Auswertung der „Klugentscheiden“-Umfrage der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO)

Priorities of German Oncologists. Results of the „choosing wisely“survey of the German Society of Hematology and Medical Oncology(DGHO). Deutsche Med. Wochenschrift 2017; 142: e124-e130.IF: 0,552

37.
Corinna Trenker, Christian Görg, Christian Jenssen, StefanKlein, Andreas Neubauer, Uwe Wagner, Christoph F. Dietrich: Sonografie in der Onkologie, eine Bestandsaufnahme. Ultrasound in oncology, current perspectives, Z. Gastroenterologie 2017; 55: 1021–1037 IF: 1,618

38.
Jörg Hoffmann, Christian Michel, Theresa Schindler, EllenWollmer und Andreas Neubauer: Rare diseases recognizable fromblood smears. Internist 2018; online July 25IF: 0,36

39.
Mössner J, Neubauer A: Monoclonal antibodies. Internist (Berl). 2019 Oct;60(10):1009-1013. doi: 10.1007/s00108-019-00680­4. IF: 0.427

40.
A. Neubauer: CAR-T-Zell-Therapie. Arzneimitteltherapie 2019;13:69-72.IF: 2.989

41.
Corinna Trenker, Christoph F. Dietrich, Stefan Klein, EhsanSafai Zadeh, Kristina Sohlbach, Andreas Neubauer, AndreasBurchert, Christian Görg: Potenzial des Ultraschalls bei allogenerStammzelltransplantation und transplantationsassoziiertenKomplikationen. Zeitschrift für Gastroenterologie 2021; DOI10.1055/a-1374-4192 IF: 1.338

42.
The SKI oncogene. In:

http://atlasgeneticsoncology.org/Genes/SKIID42303ch1p36.html
43.
Hasenfuß G, Hallek M, Neubauer A (2023) [Cardiac amyloidosis]Inn Med (Heidelb) 64:820-822 doi:10.1007/s00108-023-01575-1IF: 0.427

44.
Neubauer A (2024) [Precision medicine] Inn Med (Heidelb)65:191-193 doi:10.1007/s00108-024-01667-6IF: 0.427

45.
Mack E, Horak P, Fröhling S, Neubauer A (2024) [Precisiononcology and molecular tumor boards] Inn Med (Heidelb) 65:462-471 doi:10.1007/s00108-024-01689-0IF: 0.427

46.
Fischbach W, Neubauer A, Reinartz G (2024) [Gastrointestinal mucosa-associated lymphoma] Inn Med (Heidelb) 65:690-700 doi:10.1007/s00108-024-01715-1IF: 0.427

47.
Neubauer A, Leithold C, Nitschmann S, Jordan K (2025) [Newtargeted treatment for tumor-associated cachexia : A breakthrough?] Inn Med (Heidelb) doi:10.1007/s00108-025-01922-4IF: 0.427

48.
Neubauer A, Hallek M (2025) Zelluläre Therapieverfahren in der Inneren Medizin. Die Innere Medizin 66:777–778 doi:10.1007/s00108­025-01954-w IF: 0.427